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 Pulmonary drug delivery has been an underutilized delivery space.  Classically, 
pulmonary delivery has been employed for local delivery of small molecules for lung-centric 
respiratory diseases.  The most typical example has been the application of corticosteroids as a 
treatment for asthma.  There are multiple issues with this approach primarily focused on delivery 
as current formulations do not achieve a high amount of deposition into the lungs, which is 
countered by increased dose.  To counter this, particle engineering strategies have been 
employed to improve delivery.  By engineering our nanoparticle agglomerates, called 
NanoClusters, we have achieved increased deposition into the lungs.  Corticosteroids are poorly 
water soluble and as such, dissolve slowly.  There are lung clearance mechanisms that can 
clear these engineered NanoClusters before they dissolve, so the dissolution was assessed.  It 
was observed that NanoClusters had enhanced dissolution making them an optimal system for 
lung delivery. 
 The lungs can be employed for regional and systemic delivery and not just local.  The 
next study focused on delivery of a polymer, hyaluronic acid (HA) into the lungs.  HA of different 
molecular weights was labeled, either fluorescently or with a radiolabel, and administered to 
mice.  Labeled HA was tracked throughout the organs to determine the biodistribution of the 
polymer according to molecular weight along with determination of the pharmacokinetic 
parameters.  The optimal size was determined to be between 67 and 215 kDa for HA to achieve 
increased persistence in the lungs.  The lungs can be involved in the immune system as well in 
terms of systemic delivery.  Recent research has shown that the lungs may contribute to profile 
switching in immune cells leading to different responses.  By employing antigen presentation in 
a soluble antigen array for autoimmune diseases, there can be increased efficacy towards 
generating immune tolerance.  By co-delivering two different antigens to the lungs, there is 
amelioration of the mouse model of multiple sclerosis suggesting the lungs may be a delivery 






















1.1. Introduction  
1.1.1. Introduction to Pulmonary Drug Delivery 
 Traditional pulmonary therapies have centered on inhalation of small molecules for local 
treatment of lung diseases.  Multiple diseases including asthma, COPD, tuberculosis, and cystic 
fibrosis have classically been treated by simple small molecule formulations1.  Newer treatments 
have focused on improving inhaled drug aerosols or designing molecules with improved efficacy 
or duration of effect2.  For example, particle engineering has been employed to increase 
deposition into the lungs or to create advanced release profiles3,4.  Medicinal chemistry has 
been implemented to develop new molecules with increased duration as a result of improved 
receptor binding affinity and persistence in lung tissue after inhalation.  Even with continued 
development, there are still many challenges that remain in pulmonary drug delivery including 
poor patient outcomes and short duration of effect that will be described in further detail later in 
this chapter.  These challenges present opportunities to provide increased efficacy, faster onset, 
longer duration, and fewer side effects by improving pulmonary drug delivery systems5-8. 
 While traditional therapies for lung diseases continue to benefit from improvements in 
performance of inhaled medicines, the lungs are now being pursued for systemic drug delivery 
or for delivery to pulmonary lymphatics.  Inhaled insulin was approved for delivery into the lungs 
with the target of systemic distribution and fast acting medicines for migraines and seizures are 
near approval9.  There are some challenges with pulmonary delivery including proper 
administration and consistent dosing, but the lungs offer a novel administration route for 
compounds that are potentially challenging to deliver by other means or those that require rapid 
onset9-11.  Also, lymph nodes that drain the lungs may facilitate access to immune cells and 
could allow localized immune modulation after inhalation of immunotherapies or antigens12.  
Thus, this dissertation investigates approaches to improve delivery of drugs to the lungs by 
engineering particles and polymers as drug carriers.  
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1.1.2. Outline of Dissertation Chapters  
After an introduction to lung physiology, diseases, and treatments in Chapter 1, Chapter 
2 investigated engineered drug particles designed to facilitate aerosolization and speed 
dissolution.  Many of the small molecule drugs used in inhaled medicines are poorly water 
soluble, and there existed the potential for lung clearance mechanisms to remove the particles 
before they dissolve and produce an effect13-26.  In addition, applications such as asthma rescue 
inhalers, may benefit from rapid onset1,2.  The particle engineering strategy utilized here 
employs wet milling to create micron size particles comprised of nanoparticle agglomerates 
called NanoClusters.  This chapter explored the characterization of the NanoClusters and 
assessed the dissolution of two poorly water soluble compounds that have been developed into 
NanoClusters24-26.  Finally, this chapter utilized modeling to explain the dissolution phenomenon 
that was observed. 
Chapter 3 focused on the biodistribution and pharmacokinetics of a polymer drug carrier 
hyaluronic acid (HA).  HA has multiple available sites for chemical modification, is available in a 
wide range of molecular weights, and is naturally occurring29-40.  HA has been investigated in 
multiple other administration routes (intravenous, subcutaneous, intralymph nodal) to determine 
its pharmacokinetics30,39-49 and is beginning to gain acceptance in nebulized formulations to 
improve tolerance of the therapy50-55.  By better understanding the distribution of HA based on 
molecular weight once it enters the lungs, formulations can be modified to have increased 
persistence or other desirable properties.  This chapter explored the distribution of 5 molecular 
weights of HA (7, 30, 67, 215, and 741 kDa) labeled with either a fluorescent or radiolabel.  HA 
distribution in major organs was assessed and pharmacokinetic parameters were calculated to 
correlate HA molecular weight with absorption, distribution, and elimination. 
Chapter 4 explored HA as a carrier of peptides delivered into the lungs to treat 
experimental autoimmune encephalomyelitis (EAE).  EAE is the mouse model of multiple 
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sclerosis, an autoimmune disease where immune cells attack the myelin sheath55,56.  Strategies 
such as antigen specific immunotherapy have been developed to induce tolerance to foreign 
antigens (e.g. ‘allergy shots’)57,58, but this chapter aimed to induce tolerance to myelin self-
antigens59-61.  The lungs have recently been highlighted as an important organ in the immune 
system, affecting the activation and trafficking of immune cells62-67.  Thus, this chapter seeks to 
combine the ability to induce immune tolerance employing soluble antigen arrays (SAgA) that 
use HA to co-deliver a myelin antigen epitope and a peptide inhibiter of immune cell adhesion to 
the lungs55,56.  Clinical disease was assessed in EAE mice treated with SAgAs compared to 
positive and negative controls.  Finally, the dissertation concluded with some recommendations 
for future work and emerging opportunities in the field of pulmonary medicine. 
 
1.2. Lung Physiology  
1.2.1. Lung Anatomy and Structure 
 The lung is comprised of continually branching generations of airways ranging from 17 to 
23 generations depending on physiological location starting with the trachea then proceeding 
into bronchi then bronchioles before terminating in alveoli.  The trachea and initial bronchi have 
supporting cartilage in the form of rings to provide increased structural support.  The bronchi are 
approximately 4 to 5 mm in diameter leading into the more terminal bronchioles diameter of 
approximately 1 mm, and finally, terminating in the alveoli that are 250 µm in diameter.  The 
conducting portion of the lung consists of the uppermost airways that warm and moisten the air 
before it enters the respiratory bronchioles and the alveoli where gas exchange occurs typically 
in airway generations 20 to 23.  The airways are comprised of an inner layer of epithelium 
surrounded by smooth muscle.  The epithelium is covered in a mucus layer that is swept into 
the esophagus by cilia in the conducting airways.  A thin layer of surfactant maintains the proper 
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surface tension for air exchange in the alveoli where macrophages patrol to remove any 
detrimental particles that are deposited in the deep lung.  Figure 1.1 shows the tissue 
composition of the lung and how the different tissue layers transition in the lung.  The airways 
also consist of a basement membrane that is composed of extracellular matrix as an attachment 
for the epithelial cells and is not a biological membrane68,69.  The epithelial cells differ depending 
on their position in the lung.  In the bronchi, the epithelial cells are approximately 60 µm in depth 
with up to 10 µm of mucous above the epithelial cells.  In the next set of airways, the 
bronchioles, the epithelial cells are only 10 µm with 3 µm of solution terminating in the alveoli 
epithelial cells of only 0.1 µm with just 0.05 µm of solution9.   
Another important aspect of the lung is the different relationships it has with the other 
organ systems.  The major intersection is with the cardiovascular system as gas exchange 
occurs in the lungs as red blood cells squeeze through the capillaries surrounding the terminal 
bronchioles and alveoli.  The closeness of the cardiovascular system and the narrow barriers 
between the two allow for systemic delivery to occur.  The other major organ system associated 
with the lungs is the lymphatic network in the upper thoracic cavity including the nodes around 
the alveoli68,69.  As seen in Figure 1.8, lymph nodes form a network around the alveoli.  The 
lymph nodes are adjacent to the terminal bronchioles with lymph vessels or capillaries wrapping 
around the alveoli.  The lymph vessels can take macrophages that have exited the lungs and 



























Figure 1.1: Tissue composition of the lungs and airways.  Panel A depicts the branching and 
bifurcations that comprise the lungs down to the alveoli.  Panel B shows the tissue 
composition in the upper airways (from the outside in – cartilage, basement membrane, 
smooth muscle, eptithelial cells, mucus, lumen), while Panel C shows the lower airways 





















1.2.2. Lung Clearance Mechanisms 
The lungs eliminate materials using active transport processes including mucociliary and 
macrophage clearance, as well as passive diffusion to the bloodstream or lymph.  Mucociliary 
clearance occurs in the upper airways as ciliated cells sweep mucus up the trachea and into the 
oropharyngeal cavity, where it is typically swallowed.  Residence time in the upper airways, 
therefore, would depend on the distance from the site of deposition to the oropharyngeal cavity.  
The rate of mucociliary clearance can also depend on viscosity.  Slower and/or incomplete 
clearance of thick mucus is observed clinically, while expectorants facilitate mucus clearance.  
Further down the airways, macrophages can recognize molecules or particles in the conducting 
airways (terminal bronchioles and alveoli) below the mucociliary elevator.  Macrophages that 
have bound or phagocytosed foreign particles can then actively transport to the lymphatics 
draining the pulmonary bed.  Finally, compounds can dissolve into the fluid layer lining the lung 
epithelium and then absorb into the bloodstream.  Systemic absorption is typically fastest in the 
alveolar region, where the tissue barriers are as thin as a few hundred nanometers.  Passive 
diffusion can also provide access into the lymphatic network draining the lungs as a possible 
clearance mechanism depending on the particle or molecular size9,69.   
In terms of achieving systemic delivery from the lungs, there are several challenges that 
must first be overcome.  The first issue is that there are several layers of physiological barriers 
after a therapy has been delivered to the lung.  Mucus presents a surface gel phase and 
underlying sol phase.  A compound must dissolve and diffuse through the mucus (or lung 
surfactant in the alveolar region), then partition into and across the cell layer, before ultimately 
diffusing into the systemic circulation through the capillary bed.  These multiple barriers can 
maintain therapies in the lungs to achieve a high local concentration to increase therapeutic 
efficacy in the lungs.  These barriers compete with the multiple clearance mechanisms 
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mentioned above, which can remove these treatments from the lungs before they have a 















Figure 1.3: Lung clearance mechanisms based on position in the lungs. Mucociliary clearance 
occurs in the upper airways, where ciliated epithelial cells propel mucus from the airways into 
the oropharynx to be swallowed.  Macrophage uptake occurs in the lower airways and alveolar 
region as does an increased portion of passive diffusion, which can occur in the upper airways 













1.3. Advantages and Disadvantages of Pulmonary Delivery  
 There are several advantages to pulmonary delivery of therapies that have made it an 
enticing administration route.  As discussed above, the lungs provide a large and accessible 
target for local delivery of therapies.  Molecules have been designed to persist in the lungs or 
undergo rapid metabolism if absorbed systemically, which is an attractive approach to improve 
drug safety and efficacy.  The lungs possess up to 140 m2 of accessible surface area for 
absorption of compounds and ample blood supply, which provides an attractive portal for 
systemic drug delivery.  Delivery to the lungs helps to circumvent one potential major issue with 
systemic therapies, as pulmonary delivery avoids first pass metabolism that occurs in the liver, 
which can remove much of the active compound from the body71,72.  The lungs have a low level 
of enzymatic activity, mainly phosphodiesterase activity, especially compared to that in the liver 
during systemic administration (Table 1.1)69.   
 There are some potential disadvantages with pulmonary drug delivery that have 
hampered this area, which require continued improvement and research.  There is the 
challenge of the conditions of the respiratory system specifically the increased humidity, which 
can alter the aerosol performance of the formulation, and amplify the challenge of maneuvering 
through the airways to reach the deep lung.  Most marketed formulations suffer from extremely 
poor delivery largely due to the particle or droplet size of the aerosolized dose, which can be 
manipulated using different synthesis strategies and devices.  Only approximately 20 – 30% of 
current formulations typically reach the lungs and most is deposited into the oropharynx and 
upper conducting airways.  Particles larger than 5 um tend to deposit into the oropharynx and 
upper airways, while particles smaller than 1 um tend to be exhaled.  Poor and inconsistent 
delivery is one possible explanation for inadequate control of diseases such as in asthma, 
where up to 50% of patients have poorly controlled symptoms.  Due to the various different 
delivery systems available, each one requires a different breathing profile.  These different 
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profiles can be challenging for patients, leading to incorrect use and reduced efficacy of the 




Large surface area 
 
Different breathing profiles needed for different 
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Avoids first pass metabolism Low delivery efficiency of devices 
 
Thin physiological barrier for systemic 
delivery 
 
Multiple tissue barriers to prevent systemic 
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1.4. Lung Drug Delivery Systems 
 There are three major drug delivery systems for inhalations products: nebulizers, 
pressurized metered dose inhalers (pMDI), and dry powder inhalers (DPI)73.  Nebulizers utilize a 
liquid formulation that is dispersed by gas or sonic waves.  Nebulizers have advantages of 
typically being easy to use by utilizing only normal tidal breathing, can be adapted for high and 
low doses, and may be used to deliver combination therapies (Table 1.2).  Nebulizer 
disadvantages include a lack of portability, typically needing longer treatment times of 
approximately 10 to 20 minutes, and do not efficiently aerosolize formulations, although recent 
advances in vibrating mesh nebulizers are improving efficiency73-77.  pMDIs act by utilizing a 
propellant to aerosolize a dose from a liquid drug reservoir, which is then inhaled by the patient.  
The advantages of pMDIs include a short treatment duration, small containers so they are 
portable, no drug preparation is necessary, and dose reproducibility is high.  The disadvantages 
Table 1.1: Advantages and disadvantages of pulmonary drug delivery. 
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of pMDIs include coordination of breathing and actuation necessary for delivery, which may lead 
to improper use, upper limits for dose, insufficient means to track the amount of dose left in 
reservoir, and high oropharynx deposition when using a pMDI without a spacer.  Besides these 
drawbacks, the propellants initially used were chlorofluorocarbons (CFCs), which due to their 
depletion of ozone, have been switched to hydrofluoroalkanes (HFAs).  HFAs have different 
properties necessitating reformulation, and even now HFAs are being phased out in Europe73,78-
84.  DPIs work differently from pMDI and nebulizers, delivering a dry powder aerosol that utilizes 
the patient’s breathing to disperse and deliver the formulation.  DPI advantages are that they 
are small and easy to use with breathe actuation devices, portable, do not require spacers, offer 
short treatment duration, and have many different device forms (single and multiple doses).  
The disadvantages of DPI include requiring a high inspiratory flow rate, typically high deposition 




Delivery System Advantages Disadvantages 
DPI 
 
1. No propellants 
2. Dose counters 
3. Multiple device forms 
 
1. Can have high oropharynx 
deposition 
2. High flow rate required 
pMDI 
 
1. Short treatment time 
2. High dose-dose reproducibility 
 
1. Needs breath coordination 




1. Easy to use 
2. Dose modifications 
 
1. Time consuming treatment and 
not portable 
2. Poor aerosolization of 
suspensions 
Table 1.2: Discussion of different pulmonary drug delivery systems and their potential 
advantages and disadvantages.   
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1.5. Improving Local Lung Delivery  
1.5.1. Issues with Current Treatments 
 The development of inhaled treatments has focused on two areas: device and 
formulation design.  In terms of device design, DPIs have gained increased prevalence due to 
the more desirable properties discussed above; however, DPIs are difficult for children to use as 
high inspiratory flow rates are required to achieve optimum delivery efficiencies.  For example, 
only approximately 20% of an inhaled steroid dose is delivered into the lungs (Figure 1.4).  The 
remaining 80% is deposited in the mouth and oropharynx, where it is swallowed and enters 
systemic circulation.  Many steroid drugs have been selected because of their high first pass 
metabolism, which removes them from systemic circulation leaving only 1-10% of active 
ingredient in the blood.  Chronic use may elicit unwanted side effects, however, which can be a 
particular issue in children as systemic exposure of steroids has been linked to issues in bone 






















Figure 1.4: Deposition of corticosteroids from inhaled devices.  A majority enters the GI tract 
and a small percentage accesses the lungs to elicit therapeutic effect. 
  
There is the complicating factor of poor patient compliance in many of these inhaled 
therapies.  Previous therapies have required multiple doses, between 2-4 doses, to be taken a 
day for control therapies to maintain symptom control.  When patients skip treatments, they can 
fall out of the therapeutic window.  Also, some asthma types do not respond to steroids and up 
to 50% of patients have poorly controlled asthma symptoms by just steroids94-96.   
The other issue with current inhaled therapies focuses on the challenge of formulation.  
The first line treatment of therapies for local lung diseases such as asthma is corticosteroids.  
Corticosteroids are processed into micron sized particles, which are subsequently blended with 
lactose carrier particles so the corticosteroids are physically associated on the surface of the 
10% / 18 μg 
Inhaled Corticosteroid (ex. 180 μg) 
First Pass Hepatic 90% 
Lungs (20% / 36 μg)  
No Metabolism 
20% / 36 μg 
GI Tract (80% / 144 μg)  
First Pass Hepatic 99% 





lactose (Figure 1.5).  A high inspiratory flow rate is needed to achieve enough shear to separate 
the drug particles from the carrier lactose so the drug particles can follow the air flow for 
deposition into the lungs, while the much larger lactose particles deposit in the mouth and throat 
and are swallowed97-99.  DPIs are fundamentally different in their formulation when compared to 
pMDIs and nebulizers as both of these are wet formulations, delivering drugs in droplets.  
Today, many therapies are combination therapies to achieve 24 hour duration or a once daily 
formulation.  There are new challenges of co-formulating multiple drugs and improving 



















Figure 1.5: Current inhalation formulation strategy comprised of large carrier particles (typically 




Table 1.3: Current marketed therapies for local treatment of lung inflammatory diseases 
(asthma and COPD) including their active compound and indication. 










Asthma and COPD – 
control 









Asthma and COPD - 
control 
Once daily combination 
therapy 
Pulmicort Budesonide Asthma – control 
Corticosteroid only 
formulation 
Flovent Fluticasone Asthma – control 
Corticosteroid only 
formulation for years 4+ 
Singulair Montelukast Asthma – Control 
Treats exercise induced 
constriction 
Xolair Omalizumab Asthma (allergic) – control 
Effective treatment for 
allergic asthma subset 
and 2-4 week duration 
 
1.5.2. Particle Engineering to Improve Local Pulmonary Deposition 
Several particle engineering strategies have been employed to control deposition into 
the lung as well as alternative sustained release approaches to increase lung exposure and 
persistence or to target a specific area of the lung.  Particle engineering strategies have 
employed multiple techniques to achieve the different morphologies that provide particles with 
their improved properties including spray drying, spray freeze drying, emulsification, 
supercritical precipitation, as well as traditional micronization and blending (Figure 1.6)3,4.   
Spray drying involves atomizing the solution into a spray followed by drying and 
separation of the dried product.  Each of these steps can have different operating parameters 
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creating different particle morphologies.  Spray drying can produce particles that are amorphous 
and the process is fairly straightforward and simple, but degradation can occur due to the heat 
used in the process.  For example, spray drying has been of interest for biomolecules but can 
lead to protein denaturation or aggregation for degradation.  Spray drying has been employed 
as PulmiSphere™ technology to create low density hollow particles.  Spray drying has also 
been employed to form aggregates of crystalline drug with amorphous excipients.  Finally, spray 
drying has been utilized for sustained release as different polymers have been sprayed creating 
different properties in the particles.  Spray freeze drying has also been used to create 
amorphous or crystalline particles and this approach can be used for compounds that are more 
heat sensitive to reduce degradation.  Spray freeze drying can modulate the morphology of the 
particles in a manner that is similar, but more expensive than spray drying.   
Emulsions can be used to precipitate solid composite particles with a narrow size 
distribution that can be utilized for controlled release micro- and nanoparticle suspensions.  
Emulsions have traditionally been employed for biodegradable PLGA particles with double and 
triple phases of oil and water, but it can be difficult to scale up and remove residual solvents.  
The phases can be adjusted to create different particle morphologies.  Similarly, precipitation 
into supercritical antisolvent can create crystalline particles that are typically stable and non-
cohesive but control of the particle size can be difficult3,4.   
Micronization of drug and blending with excipient ‘carrier’ particles (e.g. lactose) is a 
proven industry standard to deal with drug crystals that are cohesive and have poor flowability 
due to electrostatic forces.  Micronization is conducted by milling (dry, wet, jet) and has 
produced a majority of the marketed inhaled products.  It can be employed for small molecules 
and has been adapted for some biomolecules, but since it is a grinding technique, it is less 
adaptable for more complex particle engineering structures including porous particles or 
composites25,26.   
17 
 
All of these particle engineering methods plus other methods allow for many different 
particle morphologies and compositions to be created.  There are large porous particles, 
aggregates, rods, fibers, solid particles and combinations of these that aim to facilitate particle 
access to the lungs.  One disadvantage is that many of particle engineering strategies were first 
employed for oral dosage forms and the solvents and excipients to create some of these 










Figure 1.6: Particles created by different particle engineering techniques generating different 
particle morphologies. Micronizing can produce smaller particles; emulsion can create hollow 
spherical particles; spray dried can generate large porous and irregularly shaped particles; 
spray freeze dried can produce dried raisin particles; supercritical antisolvent can generate large 
agglomerates of small partcles. 
 
 Many of the particle engineering techniques have focused on increasing the 
aerodynamic properties of the particles, while decreasing the density of the particles.  The 
typical method introduces porosity into the starting solid particles either by making hollow 
Spray Dried Spray Freeze Dried Supercritical Antisolvent 
Micronized / Milling Emulsion 
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particles or irregular surfaces3,4.  An alternative approach is to utilize the small drug particles as 
building blocks to generate larger, low density particles.  NanoClusters are a composition 
particle made by agglomerating solid nanoparticles into microparticles (Figure 1.7)25,26.  These 
particles have void spaces present, which allow them to act smaller aerodynamically.  
NanoClusters can increase delivery into the lungs without carrier particles (Figure 1.5), while 
minimizing delivery to the GI tract by swallowing as seen with current formulations (Figure 1.6).  
This dissertation explores the advantages of NanoClusters for rapidly dissolving steroid 










Figure 1.7: Synthesis and composition of NanoClusters.  Large particles are reduced in size to 










1.6. Increasing Persistence of Pulmonary Therapies 
1.6.1. Drug Design  
The NanoCluster formulations explored in this dissertation have the potential to enable 
rapid onset.  On the other hand, many current inhaled therapies have a limited duration of effect 
requiring multiple doses per day.  The requirement of frequent dosing can discourage patient 
compliance, which can lead to poor patient outcomes95,96.  To counter this trend, there has been 
a drive for once-daily therapies, and to achieve this, chemistry has been utilized primarily 
focusing on three particular drug classes: corticosteroids11, muscarinic antagonists5, and beta-2 
agonists6,7.  In this section, medicinal chemistry approaches to prolong the effect of inhaled 
drugs then transitions to current physical chemistry approaches, motivating the exploration of 
hyaluronic acid delivery to the lungs explored in this dissertation (Chapter 3).   
Medicinal chemistry approaches for inhalation have focused on some common 
molecular motifs adapted from oral compounds.  Lipinski’s, Gleeson’s, and Waring’s rules are 
based on molecular weight, hydrophobicity, and heteroatoms related to hydrogen bond donors 
and acceptors.  By looking at these molecular properties, there is a certain desirable range of 
characteristics to achieve optimal oral delivery of the molecule.  By comparison, approved 
inhaled therapies exhibit a slightly higher molecular weight and are less hydrophobic, although 
this data is thought to be skewed since a large number of inhaled drugs are thought to be a by-
product of selection bias toward traditional oral compounds.  These design criteria have been 
extrapolated to create more effective and persistent compounds for inhaled therapy100-104.     
1.6.1.1. Traditional Drugs and Progression to Current Molecules 
Corticosteroids including budesonide, mometasone, and fluticasone, have been the 
standard treatment option for asthma to locally reduce inflammation in the airways.  Steroids are 
able to enter the cells in the airways as they have high lipophilic character and can permeate 
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the cell membrane.  Corticosteroids, once in the cell, bind to the glucocorticoid receptor present 
on the nucleus, which is then taken into nucleus.  The internalized receptor-ligand complex 
binds upstream of the target genes and modifies protein transcription and reduces inflammatory 
gene expression and increases anti-inflammatory gene transcription.  Steroids typically act on 
the epithelial cells reducing inflammation and hyperresponsiveness though they do little in terms 
of treating the underlying condition.  Since inflammation and hyperresponsiveness are hallmarks 
of both asthma and COPD, corticosteroids are effective treatments for both diseases105,106. 
Beta-2 agonists (BA) have been utilized since the 1960s with the first use of albuterol.  
BAs act as bronchodilators as they stimulate β2 receptors in the smooth muscle layer of the 
airways.  As BAs bind with the receptors, adenylyl cyclase becomes activated through 
stimulatory G protein.  The activated G protein causes an increase in cAMP levels leading to 
bronchodilation6,107.   
BAs have been developed now into 3 different categories: short acting BAs (SABAs), 
long acting (LABAs), and ultra-long acting (ULABAs).  SABAs including albuterol were the first 
generation of BAs that were developed in the 1960s typically working 3 to 4 hours but potentially 
working up to 6 hours.  Due to their physicochemical properties and binding ability, they have a 
quick onset of activity typically on the order of 5 minutes.  They are more effective for treating 
asthma brought on by exercise, cold air, and allergens. LABAs such as formoterol and 
salmeterol are the second generation and typically have 12 hour duration.  LABAs have an 
increased binding constant compared to SABAs combined with a decreased dissociation 
constant, which is a reason for their improved efficacy and longer duration.  In addition, to the 
improved binding, their physicochemical properties are such that they can form a depot in the 
cell membrane allowing the drug to diffuse continuously to the receptor further increasing its 
duration of effect.  Formoterol has similar onset to albuterol, while salmeterol has a slightly 
longer onset time of approximately 30 minutes.  LABAs have been continually refined for 
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increased efficacy and duration leading to ultra long acting BAs such as indacaterol and 
vilanterol.  These ULABAs have duration of 24 hours again due to increased binding affinity 
between the drug and the beta 2 receptor6,108-111.  
 
Table 1.3: Progression of β2 agonists from short acting to long acting to ultra-long acting and 
their associated chemical structure.   
Name Classification Chemical Structure 
Albuterol Short acting 
 
Epinephrine Short acting 
 
Formoterol Long acting 
 


















There are some common motifs found throughout BAs.  The design criteria included in 
newer generations in development includes the use of benzylic hydroxyl groups to improve 
potency, intrinsic activity, and selectivity.  The next criteria for rational design included the use of 
another basic motif in the chain, which increased plasma half-life.  Half-life was continually 
refined by altering lipophilicity to achieve high plasma half-life that corresponded to high lung 
half-life.  The progression of BAs has followed the molecular design rules by increasing in 
molecular weight and increasing the number of heteroatoms, oxygen and nitrogen, to decrease 
lipophilicity3,110.  There have been further structure elucidations to improve delivery including the 









Table 1.4: Some common molecular motifs in β2 agonists that elicit therapeutic effect and their 
associated chemical structure.  The column on the right depicts the aromatic group (Ar) off the 










Muscarinic antagonists (or anticholinergics) are another class of bronchodilators that are 
used more often in COPD compared to asthma due to their lower efficacy in treating asthma 
then BAs.  Muscarinic antagonists including tiotropium and ipratropium are specific antagonists 
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for muscarinic receptors to reduce cholinergic nerve related bronchoconstriction.  Muscarinics 
inhibit the action of the cholinergic nerve but have no direct action on inflammatory mediators 
such as histamine and leukotrienes.  They are typically less effective for treating asthma 
brought on by allergen and exercise by treating airway narrowing, which is currently the only 
reversible symptom of COPD5,115.  Muscarinic optimization has followed the approach taken for 
BAs.  Ipratropium was first developed and has a duration of up to 6 hours, while the latest drug, 
tiotropoum, has a duration of 24 hours116.  Many of the muscarinic antagonists employ a 
quaternary amine, which due to the permanent positive charge inhibits transport across the cell 
layers from the lung to enter systemic circulation.  Another advantage of the quaternary amine, 
is that any drug entering systemic circulation is rapidly metabolized and then cleared helping to 
reduce unwanted side effects5.  
 
Table 1.5: Progression of muscarinic agonists from short acting to long acting to ultra-long 
acting and their associated chemical structure.   
Name Classification Chemical Structure 

























BAs are now being combined with other therapeutics including steroids and muscarinic 
antagonists to create a complete therapy for both controlling and relief to improve patient 
compliance in the desire to achieve a once daily formulation.  There are several different options 
that have been employed as combination therapies which are typically corticosteroids with BAs 
(budesonide with formoterol, Symbicort, fluticasone with salmeterol, Advair, mometasone with 
formoterol, Dulera, and fluticasone with vilanterol, Ellipta) and corticosteroids with muscarinic 
antagonists.  Both of these treatments work in synergistic forms as the steroids reduce the 
inflammation in the airways and the beta 2 agonists and muscarinic agents cause 
bronchodilation.  Combination therapies have improved efficacy over single therapies with 
fluticasone/salmeterol having fewer asthma symptom days and exacerbations.  
Budesonide/formoterol combination had more days with asthma control, increased time 
between exacerbations, higher volume of air expelled from the lungs, and  a lower dose of 






1.6.2. Other Approaches to Sustain Lung Delivery 
Besides medicinal chemistry approaches to increase duration, there have been new 
drug delivery strategies employed to achieve increased lung deposition and persistence.  There 
have been numerous examples of engineered polymeric particles120.  Polymeric microparticles 
and porous particles have been utilized as carriers especially with poly lactic glycolic acid 
(PLGA) given its ability to have a modulated degradation.  Porous PLGA particles loaded with 
budesonide had a better performance in terms of reduced inflammation compared to nonporous 
PLGA budesonide loaded particles121.  Hydroxypropyl-β-cyclodextrin has been incorporated as 
an excipient to reduce insulin release and to modulate powder aerodynamic properties.  These 
particles had increased deposition into the deep lung and alveoli, which allowed rapid systemic 
onset compared to an insulin solution123,124.  Nanoparticle medicines using similar excipients 
have also been explored to increase persistence in the lung.  Nanoparticles typically utilize a 
different delivery strategy such as liquid formulations via nebulization or encapsulation in carrier 
particles120.  Tobramycin PLGA nanoparticles have been embedded in lactose particles with 
alginate, polyvinyl alcohol, and chitosan used to modulate the size and release properties of 
tobramycin from the nanoparticles to increase persistence to 1 month124.  Studies on PLGA 
particles coated in chitosan reported increased lung persistence and residence time potentially 
due to increased mucoadhesiveness.  Chitosan is a permeation enhancer and as such, is not 
recommended for use in inhalation as it can alter the tight junctions in the lung.   Other 
excipients including chitosan, alginate, and lipids have been employed to sustain delivery.  
PLGA has been extensively studied as an excipient in other products, but not for inhalation, and 
it has yet to be incorporated into an approved inhalation product120. 
Liposomes have been explored for sustained pulmonary delivery of drugs as well.   
Naturally occurring lipids in lung surfactant and tissue have been employed and appear to be 
well accepted in the lung.  Multiple drug classes have been encapsulated within liposomes 
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including antibiotics, bronchodilators, anticancer agents, and proteins120.  Arikace®, amikacin  
encapsulated in liposomes, is in clinical trials for cystic fibrosis patients with infections and are 
comprised of cholesterol and dipalmitoylphosphatidylcholine in a 1:2 ratio.  The liposome 
formulation provided slow sustained release, while free amikacin was found to interact with 
mucus decreasing efficacy and requiring higher dosing125,126.  Pulmaquin®, a ciprofloxacin 
liposome formulation in clinical trials, provides a combination effect of burst release and 
sustained release over 24 hours to avoid some of the irritant reactions resulting from free drug 
exposure127.     
The final method of sustained delivery utilizes conjugation to polymers via PEGylation 
and dendrimers.  Different molecular weights of PEG have shown different clearance properties 
from the lungs.  PEG 2 to 5 kDa in length has mucus penetrating abilities, while increased PEG 
size (10 kDa) was reported to stick in the mucus.  Mutliple PEGylation sites on the same protein 
and longer PEG chains, 5-12 kDa, was also reported to slow absorption from the lungs128,129.  
PEGylation of proteins including insulin and rhG-CSF also appears to slow absorption from the 
lungs, extending the plasma half-life130-132.  PEGylation increases hydrophilicty and steric 
hindrance, which may decrease degradation rates, since PEGylation has been used to protect 
peptides from proteases in the lung and increase systemic absorption after delivery to the lungs.  
Calcitonin PEGylation using 1 to 5 kDa PEG increased stability in the lungs by 1000 times, 
which increased systemic bioavailability 8 fold120.  PEG has also been conjugated to antibodies 
to increase their residence time in the lungs.  IL-17A Fab and anti-IL-17A had 40 kDa PEG 
conjugated, which increased their persistence from 1 day to 2 days.  The PEG antibodies 
remained stable in the lung lumen and also reduced associated inflammation compared to the 
native proteins133.  By conjugating PEG, one hypothesis is that there is increased adhesion to 
mucus and decreased macrophage uptake instead of larger sizes or decreased enzymatic 
activity.  Small molecule drugs have undergone PEGylation as well including prednisolone that 
utilized a hydrolysable ester bond.  By conjugating 2 kDa PEG, the prednisolone absorption rate 
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dropped almost 8 times across the lung tissue barrier, which was thought to result from an 
increase in molecular size134.   
Dendrimers have also been investigated as a means to extend the persistence of drugs 
in the lungs.  Drugs can be encapsulated or conjugated to the surface of dendrimers using the 
unique chemistry groups or through electrostatic interactions.  Polyamidoamine dendrimers had 
methylprednisolone conjugated that reduced lung inflammation by remaining in the lungs for 
one week135.  Dendrimers conjugated with PEG (11, 22, and 78 kDa) had differential access to 
different body compartments based on their molecular weight.  The smaller molecular weights 
had increased systemic exposure compared to larger dendrimers as facilitated by the more 
rapid transport into the blood from the lungs.  The 78 kDa dendrimer had lung persistence up to 
7 days and remained relatively intact in the lungs136.  Other work has utilized a 56 kDa 
PEGylated polylysine dendrimer with doxorubicin conjugated, which sustained drug levels over 
the course of one week compared to the free drug, which was rapidly removed.  These 
conjugates yielded complete remission of lung tumors compared with high levels of toxicity with 
the free drug137. 
 Hyaluronic acid (HA) is another polymer besides dendrimers and PEG that has been 
employed to improve pulmonary delivery.  Cisplatin-hyaluronan conjugates have been utilized to 
increase local concentrations of drug in the lung compared to cisplatin delivered 
intravenously138.  HA has been employed in nebulized formulations as well to decrease lung 
inflammation and improve patient outcomes50-54.  HA is available in many varied molecular 
weights and is a natural biopolymer, making it an attractive candidate for sustained lung 
delivery.  Thus, Chapter 3 of this dissertation explores the effect of HA molecular weight on lung 
retention and subsequent biodistribution.  HA is then used as a carrier molecule for delivering 




1.7. Accessing Different Body Compartments from the Lungs  
1.7.1. Allergy Treatments and Antigen Specific Immunotherapy (ASIT) by Employing 
Pulmonary Drug Delivery 
 As mentioned earlier, the lungs play a significant role in immune disease resulting from 
both exogenous and endogenous antigens62-67.  Antigen specific immunotherapies (ASIT) have 
been explored recently as a strategy for restoring immune tolerance in autoimmune diseases.  
Classically, subcutaneous injections of allergens has been employed to gradually desensitize 
the immune system (e.g. ‘allergy shots’)58,139.  A similar type of ASIT has been tried for 
autoimmune diseases as well.  Different antigenic peptides are being employed in an attempt to 
desensitize the autoimmune response in diseases such as rheumatoid arthritis, type-1 diabetes, 
and lupus60-62. 
The lungs are exposed to the outside environment and have mucosal membranes lining 
the surface, which offers a first line of defense as protection from foreign antigens.  The lungs 
also contain a mucosal immune system capable of processing foreign antigens and introducing 
them to the effector cells to elicit the appropriate response.  The mucosal immune system 
includes the mucosa-associated lymphoid tissue (MALT).  MALT encounters a large number of 
foreign antigens, and it functions to prevent damage to surrounding native cells.  MALT is 
distinct from the systemic immune system, and the immune cells between these two systems 
are believed to have separate populations with limited crossover to decrease unwanted immune 
responses140-142. 
 Classically, the spleen and lymph nodes have been considered secondary lymphoid 
organs, where immune cells traffic to become activated and primed.  The lungs have recently 
been implicated in a ‘Hub and Spoke’ model for the immune system.  The ‘Hub and Spoke’ 
hypothesis proposes that systemic immune cells or those present in secondary lymphoid organs 
31 
 
including the lymph nodes and spleen have to be activated before eliciting a response62,63,65.  
Next, immune cells are imprinted with a tissue ‘zip code’ enabling their migration to target 
organs, which is proposed to happen in the lungs.  This process is called ‘licensing’.  The 
immune cells transport from the hub (lungs) to the different spokes depending on the 
autoimmune disease, such as the brain for MS, pancreas for type-1 diabetes, and the large 
intestine for irritable bowel disease67.  One study tracked the injection of activated immune cells 
specific to CNS antigens.  Depending on the site of injection there was a difference seen in 
symptoms and onset of symptoms.  Cells administered intravenously did not produce central 
nervous system (CNS) symptoms until 5 days post dose.  When these same cells were 
administered directly into the CNS, there were no observable symptoms.  Finally, if these cells 
were administered into the lungs (hub), it took approximately 1 day for the CNS symptoms to be 
elicited66.   
T cells have been implicated as primary players in the ‘Hub and Spoke’ hypothesis.   T 
cells must become ‘licensed’, expressing correct integrins, which are key components directing 
T cell migration.  In experimental autoimmune encephalomyelitis (EAE), there is minimal direct 
evidence of licensing of immune cells though evidence is increasing.  If licensing is in fact 
occurring in the lungs as a ‘hub’, drug delivery to the lungs offers the potential for crosstalk 
between the mucosal immune system and systemic immunity via the ‘Hub and Spoke’ 
hypothesis.  Regardless of the mechanism, the lungs offer an interesting opportunity to shift 
immune profiles, leading to modification of the immune response throughout the body65-67. 
There are practically no reports of ASIT pulmonary delivery.  The closest applications to 
pulmonary ASIT have primarily focused on cancer treatments and treatment of type-1 diabetes, 
but are not specifically ASIT.  Several previous products for inhaled insulin for type-1 diabetes 
(Exubera and now Afrezza®) will be described in more detail in the following section143.  These 
are not classical ASIT as they do not induce hyposensitization of the immune system by 
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applying an antigen but serve to replace loss of endogenous insulin production by pulmonary 
administration.  The recent literature suggests ASIT delivered to the lungs may have increased 
efficacy compared to standard delivery routes when treating autoimmune disease.   
  
1.7.2. Systemic Exposure After Pulmonary Delivery 
There are different design criteria to consider when attempting systemic delivery through 
the lungs.  Small molecule compounds compared to large molecule compounds will have 
different clearance and ability to cross the physiological barriers in the lung as discussed 
previously.  The molecular weight, charge, and hydrophobic character of molecules often dictate 
the rate of passage through the lungs into systemic circulation.  Even large proteins, however, 
can be delivered to bloodstream after inhalation and the understanding these dynamics is 
essential to drug delivery.  
For small molecule drugs, there is one major property to consider which increases 
systemic absorption.  Increased hydrophilicity corresponds with an increased half-life in terms of 
absorption of the initial dose.  Drugs with a lipophilicity of approximately 0 – 4 for a log P (and 
more so a log P of 1-3) corresponds to a half-life on the order of a few minutes.  Drugs with a 
log P of -2 - -4 that correlates with fairly hydrophilic compounds have a half-life of approximately 
70 minutes.  The other property that one might consider for systemic absorption is molecular 
weight.  However, when looking at the molecular weight range of 100 – 1000 Da, the typical size 
for small molecules, there is no correlation besides lipophilicity.  Again, the lipophilic drugs have 
a shorter half-life compared to hydrophilic compounds.  There are only a few compounds 




For inhaled systemic peptides and proteins, there are several factors to take into 
account.  The exact mechanism of large molecule absorption is not known but there are several 
theories.  With peptides, there is the possibility that they could pass through the cells via the 
tight junctions even including molecules up to 2 nm in size, which includes insulin in the upper 
airways.  Another possibility in the alveolar region is that a vesicle forms in the fluid that enters 
into the cell.  The vesicle can pass through the cell to the interstitium where the process 
happens again allowing access to the blood.  Molecules can potentially access the lymph from 
the interstitium depending on their size.  There are two major examples of systemic absorption 
of large molecules, insulin and human growth hormone (HGH).  Insulin Inhaled insulin has faster 
pharmacokinetics than subcutaneous injected insulin both in terms of absorption and clearance.  
Insulin has a narrow therapeutic window, which complicates the aerosol delivery of it besides 
the earlier issues with the delivery device.  Insulin also had some issues with stimulating cellular 
growth in the lungs, which had a slight detrimental effect on breathing.  HGH had a lower 
bioavailability when inhaled compared to subcutaneous injection (only ~10%), but it achieved 
increased growth in rats without seeing abnormal histology in the lungs for up to 28 days.  An 
example of an inhaled peptide is leuprolide acetate that stimulates the pituitary gland.  It had a 
bioavailability between 35 – 55% and had levels in the lungs over 12 hours.  Inhaled insulin, 
which is approximately 5 times larger in size reached a maximum in only 15 minutes.  This may 
have been a by-product of the formulation as it was a pMDI143. 
  
1.7.3. Lymphatic Exposure After Pulmonary Delivery 
 The final compartment of interest that may be accessible through the lungs is the 
lymphatics.  Research has suggested that in the alveolar region, vesicles can form in the fluid 
layer lining the cells for passive transport across this tissue barrier (Figure 1.8).  Once the 
vesicle transverses the cell and releases cargo into the interstitium, molecular weight can 
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determine its ultimate end point as molecules larger than 25 kDa may avoid absorption into the 
blood stream and enter the lymphatics.  In the lungs, the interstitium is a passageway where the 
lymph is transported around a bundle of alveoli leading to a lymph node higher up in the 
respiratory tree.  This transport mechanism has been observed with labeled polymers that have 
been investigated, especially for cancer therapies143.   
The alveolar region also has macrophages patrolling to remove foreign particles and 
antigens that can participate in active transport to the lymphatics.  The macrophages in the 
alveolar region have closer access to the lymphatic network with ducts and nodes just outside 
the alveolar sacs.  There is also less of a tissue barrier in the alveolar region as the epithelium 
layer is <1 µm in thickness compared to >10 µm in the upper airways with the addition of fibrous 
and smooth muscle tissue9.  Solid lipid nanoparticles have been shown to access the lymphatics 
as potential treatments for cancer and metastases and (<200 nm) can rapidly access different 
areas of the pulmonary lymphatic network144. 
There are multiple nodes that can be accessed from the lungs including the hilar, 
mediastinal, carinal, and aortic nodes.  Liposomal formulations for the treatment of cancer have 
gained particular interest as the lymphatics are implicated in metastases.  Pulmonary delivery 
and associated lymph drainage can by-pass some of the problems with conventional 
chemotherapeutic delivery namely off-target toxicity and poor penetration into the lymphatics.  
For example, pulmonary delivery of a liposomal formulation of paclitaxel and a vitamin E analog 
resulted in decreased mammary tumor burden, fewer cells were positive for CD31 and Ki67 
suggesting an inhibition of lymphatic metastases.  Other work has focused on liposomal delivery 
of this vitamin E analog with another chemotherapy drug, which resulted in prolonged survival 
rate by a decreased tumor progression.  Liposomes have also been combined with radioactive 
markers to improve diagnostics.  These radioliposomes were administered to wild boars and 
provided information on the deep lung and associated lymphatics that was unavailable from 
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conventional diagnostic methods.  Similarly, radiolabeled SLNs accumulated in the inguinal 
node of rats and remained in the lungs after 4 hours whereas free radiolabel was mainly cleared 













Figure 1.8: Structure of the lung lymphatics. A depicts the lymph nodes around the alveoli.  B 
shows a close-up of the conducting airway and accessing the lymph.  1 is a vesicle forming from 
the lung fluid passing through the epithelial cell (2) before entering the interstitium.  At 4 the 
molecule enters the cells surrounding the blood vessel before passing through it (5) and 
depositing into systemic circulation.  Between 3 and 4, molecules >25 kDa or having high 


















1.8. Pulmonary Delivery Needs  
There are many different areas for improving pulmonary delivery.  The lung is not a 
stand-alone organ but is tied into multiple organs and systems in the body.  This dissertation 
focuses on physical approaches to address specific pulmonary delivery needs.  Particle 
engineering is explored in Chapter 2 to improve aerosol deposition and provide an increase in 
dissolution by harnessing microparticles comprised of agglomerated nanoparticles 
(NanoClusters).  In Chapter 3, the molecular weight of the polymer hyaluronic acid (HA) is 
explored as a physical approach to achieve sustained exposure in the lung.  Finally, since the 
lungs have recently been implicated in the immune system, Chapter 4 of this dissertation 
investigates pulmonary ASIT therapy applied to an autoimmune disease, experimental 
autoimmune encephalomyelitis (EAE) in an effort to induce antigen-specific immune tolerance.  
Physical approaches to improving delivery of pulmonary therapeutics offer new treatment 
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 Corticosteroids are the first treatment option for several particular respiratory diseases 
including asthma as they treat the associated airway inflammation.  With the prevalence of 
asthma increasing throughout the United States from 20 to 30 million patients over the past 
decade and expected to increase to almost 400 million patients worldwide in the next decade, 
improvements need to be made to continue to treat this growing patient population1-3.  Another 
compounding factor is that a significant portion of patients (almost 50% of both children and 
adults) have poorly controlled asthma symptoms1.  Improvements are necessary in the delivery 
of corticosteroids.  The delivery methods include dry powder inhalers (DPIs), pressurized 
metered dose inhalers (pMDIs), and nebulizers.  DPIs are increasing in usage as pMDIs use 
environmentally harmful propellants and nebulizers require long dosing times of 10 – 20 
minutes.4   
In current DPI corticosteroid formulations, only approximately 20% of the delivered dose 
reaches the lung where it elicits its therapeutic effect.  The remaining 80% is deposited in the 
mouth, oropharynx, and throat where it is swallowed and enters systemic circulation.  To 
counter the decreased delivery efficiency of corticosteroids, higher doses are administered to 
elicit the therapeutic effect and treat the patient’s symptoms.  The 80% that encounters first 
pass metabolism through the liver has 90 – 99% of the plasma levels removed, but there still 
remains a significant portion present that can provoke unwanted side effects5.  These side 
effects and systemic delivery are of especial importance when these medications are used for 
children.  Children have a slightly higher prevalence of asthma than adults (10% to 8%), and 
systemic corticosteroids are more harmful in their developing bodies.  Corticosteroids influence 
the developing skeletal structure potentially leading to decreased bone mass, suppression of 
the adrenal glands, and increased bruising of the skin all of which are a major concern in 
children5,6.   
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Aerosol delivery from DPIs depends on the particle size of the drug.  Particles larger 
than 5 microns in diameter are typically deposited in the mouth, oropharynx, and throat due to 
inertial impaction, while particles smaller than 1 micron are more prone to exhalation after 
delivery.  Only particles between 1 and 5 microns in size have the necessary properties to reach 
the bronchial tree and lung periphery to improve patient response7.  There have been multiple 
particle engineering technologies employed to manipulate the size of drug particles to improve 
delivery8-13.  There are bottom-up methods including precipitation, solid dispersions14-16, spray 
drying and spray freezing into liquid14,17-21 as well as top-down methods such as homogenization 
and milling18,21-23.  Some bottom-up methods using precipitation can involve solvents24, which 
add the burden of solvent removal and disposal after processing and before use by patients25.  
Spray drying allows more precise control of particle size but may be an issue if the product is 
thermally labile17 or insoluble in the desired processing media.  Bottom-up methods including 
some precipitation methods and spray freezing into liquids can produce amorphous compounds.  
Amorphous compounds tend to be less stable than crystalline forms and can spontaneously 
revert to a lower energy crystalline form.  Of course, changes in drug morphology over time are 
not desirable and may alter the properties of the drug performance19.  Finally, bottom-up 
methods can be more difficult to scale up to the large amounts needed in the pharmaceutical 
industry23.   
Top-down approaches include methods such as milling21 and homogenization23.    Milling 
can be further broken down into dry and wet milling26.  Dry milling includes jet milling, which has 
the tendency to create surface defects, potentially increasing powder electrostatics27.  Wet 
milling can reduce surface defects by allowing some recrystallization to occur28.  One such top 
down technology is called NanoCrystal®, where the drug compound is milled with surfactants to 
create and maintain individual nanoparticles in an effort to achieve more rapid dissolution29-31.  
The strategy behind many of these techniques is to decrease particle size to increase surface 
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area18,32.  One potential issue with using surfactants in aerosol formulations is that surfactants 
can have side effects in the lungs of patients32. 
Corticosteroids have another delivery challenge as they are poorly water soluble drugs.  
There are multiple clearance mechanisms in the lung that can remove the drug particles before 
they can elicit their effect.  Mucocilliary clearance can remove undissolved particles from the 
upper airways as the ciliated cells lining these airways escalate the mucus lining the airways to 
the mouth.  Macrophages patrol the alveoli region engulfing microparticles that could potentially 
harm these delicate cells.  Increased surface area of corticosteroids should accelerate drug 
dissolution into the solution phase lining the lung allowing the drug to diffuse to target receptors 
and elicit their effect before they are removed by clearance mechanisms33-35.   
 This work will analyze two poorly water soluble steroids, budesonide36 and danazol37 as 
model compounds to test increased dissolution by particle engineering by forming nanoparticle 
agglomerates, called NanoClusters through wet milling.  Since they are agglomerates, 
NanoClusters38-40 offer both micronized particle and nanoparticle properties.  NanoClusters 
could, therefore, provide an excipient free alternative to strategies such as NanoCrystal® 
technology30,31  Here, we investigate if increased surface area of NanoClusters improves 
dissolution of poorly water soluble compounds in comparison to micronized drug particles. 
 
2.2. Materials and methods 
2.2.1. Materials 
Budesonide micronized stock (Bud) was obtained from Sicor de Mexico (Lerma, 
Mexico). Danazol micronized stock (Dan) was purchased from Voigt Global Distribution Inc 
(Lawrence, Kansas).  Pluronic® F-68 was obtained from BASF (Florham, New Jersey).  All 
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water used was deionized (DI) water from a Labconco Pro PS system.  All other chemicals and 
materials including acetonitrile, sodium lauryl sulfate, 0.1 μm pore size Whatman nylon filters, 
and Beckton Dickinson 3 mL plastic syringes, were purchased from Fisher Scientific. 
2.2.2. NanoCluster Synthesis by Wet Milling  
Budesonide and danazol NanoCluster suspensions were synthesized using a Netzsch 
MiniCer Media Mill (NETZSCH Fine Particle Technology, LLC, Exton, PA). The mill was run with 
several predetermined process parameters including a grinder speed of 2772 rpm, a chiller unit 
temperature between 6 and 8°C, a mill temperature of 18°C, and a mill pressure of under 2 bar.  
The drug suspensions were milled using 200 µm YTZ® (yttrium treated zirconium) grinding 
media from Tosoh Corp., Tokyo, Japan.   
Budesonide and danazol micronized stock were each suspended in nitrogen purged DI 
water to reduce the likelihood of oxidation during milling.  Either drug (3.25 g) was added to 390 
mL of nitrogen-flushed DI water.  The powder was wetted by introducing drug slowly, while 
continuously stirring, and NanoClusters were produced by grinding with no added excipients.  
Both budesonide and danazol samples were collected at 5, 10, and 15 hours.  Thirty mL of the 
suspension was collected at each time point with 10 mL deposited into three 20 mL antistatic 
vials.  Upon completion, the remaining suspension was collected into 20 to 25 antistatic vials.  
Nanoparticle suspension samples were produced by milling in 0.1% (w/v) Pluronic® F-68 
solution30,31 until a mean diameter of 150 to 200 nm was achieved.  Samples were immediately 
frozen in liquid nitrogen and maintained at a temperature of -80 °C.  Samples were lyophilized 
for 72 hours at a temperature of -72 °C at a vacuum of <300 millitorr (VirTis Feezemobile-12XL, 





2.2.3. NanoCluster Particle Size and Morphology  
 A LEO 1550 field emission scanning electron microscope (SEM) was used to evaluate 
the particle size and morphology of the NanoCluster powder compared to the micronized stock 
and to the nanoparticle suspension43.  Samples were sputter-coated with gold for 3 min. 
Dynamic light scattering (DLS) (Brookhaven Instruments Corp., ZetaPALS, Holtsville, NY) was 
performed to determine individual particle size comprising the agglomerates43.  To better 
estimate the size of the nanoparticles and not the agglomerates, 0.5 mL of the milled 
suspension was diluted to 10 mL with 0.1% (w/v) Pluronic® F-68 solution.  The suspension was 
then sonicated for 30 s at an amplitude of 20% with a microtip probe sonicator (Fisher Scientific, 
Sonic Dismembrator, Pittsburgh, PA) prior to analysis. The agglomerated NanoClusters were 
sized using micro flow imaging (MFI) (DPA 4100/4200 from Brightwell Technologies, Inc. 
Ottawa Canada) with Flow Microscope MVSS version 2 software.  Samples were suspended in 
0.01% sodium lauryl sulfate to ensure particles did not stick in the flow cell while maintaining a 
particle concentration of approximately 900000 counts/mL.   
 
2.2.4. Surface Area Determination Using BET 
Surface area was determined via the BET (Brunauer, Emmett and Teller) Theory using a 
TriStar 3000, Micrometrics Gemini 2375 V 5.01, Norcross, GA connected to a computer running 
Star Driver (version 2.03).  The surface area for the NanoClusters was measured for all 
powders by nitrogen adsorption and compared to that of the micronized stock drug and 
nanoparticle suspension. Prior to surface area measurement, a known mass of the sample 
powder (120 ± 30 mg) was placed in a sample tube.  Another reference tube filled with 3 mm 
spherical glass beads was used as a reference.  Liquid nitrogen was used to maintain the 




2.2.5. Determination of Degradation Using HPLC-UV 
 The chemical stability of the NanoCluster powder was determined by chromatographic 
analysis. The HPLC-UV system consisted of a Shimadzu CBM-20A system controller, LC-10AT 
solvent delivery pump, SPD-10A UV detector, and SIL-10AxL autoinjector.  Chromatograms 
were acquired and analyzed using Shimadzu Class vp 7.4 software. A Kromasil C8 column (100 
x 4.6 mm) was used for budesonide separation, while a Hypersil C18 (100 x 4.6 mm) was used 
for danazol.  The powders used an isocratic system with a mobile phase of 55/45 
acetonitrile/water at a flow rate of 1.1 mL/min.  Detection was performed at 244 nm for 
budesonide, and danazol was detected at 288 nm.  Samples of NanoClusters and micronized 
stock powder were made at a concentration of 250 µg/mL in acetonitrile and 30 µL was injected. 
The spectra showed a characteristic budesonide peak with a retention time of 4.55 min and a 
degradant peak with a retention time of 2.72 min.  Danazol had a retention time of 9.2 min and a 
degradation peak at 6.35 min. Percent degradation was determined using the peak area of the 
degradant relative to the total peak area40,41,43.  
𝐷𝑒𝑔𝑟𝑎𝑑𝑎𝑡𝑖𝑜𝑛 𝑃𝑒𝑟𝑐𝑒𝑛𝑡 =
𝐴𝑈𝐶 𝑜𝑓 𝑑𝑒𝑔𝑟𝑎𝑑𝑎𝑛𝑡
𝐴𝑈𝐶 𝑜𝑓 𝑝𝑎𝑟𝑒𝑛𝑡 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑
  𝑋 100 
2.2.6. NanoCluster Crystallinity Determination Using Powder X-ray Diffraction 
(PXRD) 
PXRD was used to determine the relative crystallinity of the NanoClusters compared to 
the miconized stock material.  PXRD was performed using a monochromated CuK radiation 
(= 1.54178 Å) on a Bruker Proteum Diffraction System equipped with Helios multilayer optics, 
an APEX II CCD detector or a Platinum 135 CCD detector and a Bruker MicroStar microfocus 
rotating anode x-ray source operating at 45 kV and 60 mA.  The powder sample was suspended 
in Paratone N oil then loaded on a nylon loop.  The loop was then loaded on the goniometer 
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where either 3 or 2, 180° 1 minute scans (based on the detector) were taken using the Bruker 
Apex2 V2010.3-0 software package.  Scans were taken at 30°, 60° and 90° with the detector 
50.0 mm away.  The patterns were analyzed using the Bruker EVA powder diffraction software 
package version 13.043. 
 
2.2.7. NanoCluster Analysis Using Differential Scanning Calorimetry (DSC) 
DSC was performed to determine any thermal transitions of the NanoClusters compared 
to the micronized drug.  DSC was performed on a Q100 DSC (TA Instruments).  Approximately 
3 to 5 mg of each sample was loaded into an aluminum hermetic pan.  DSC was performed 
from 40 °C to 300 °C using a ramp of 10 °C per min for both budesonide and danazol43. 
 
2.2.8. Dissolution of NanoCluster Dry Powder 
 Dissolution was performed using a Distek 2100A dissolution tester with temperature 
control system.  Dissolution medium was 900 mL of 0.25% sodium lauryl sulfate solution.  
Approximately 25 mg of powder was wetted then added to the dissolution vessels mimicking the 
USP Type II paddle method (37 °C + 0.5 °C, paddle speed of 75 rpm, and paddle depth of 2.5 
mm from the bottom of the vessels).  Three mL samples were taken at 5, 10, 15, 20, 30, 45, and 
60 minutes with dissolution medium added to replace the sample volume.  Samples were 
immediately filtered using a 0.1 µm nylon filter to remove any undissolved drug particles and 





2.3. Results and discussion 
2.3.1. Wet Milling Created Nanoparticle Agglomerates 
 The wet milling process created nanoparticle agglomerates, called NanoClusters, which 
were confirmed using SEM43.  There was a definitive decrease in particle size due to milling 
when compared to the stock micronized drug particles (Fig 2.1 and 2.2).  The NanoClusters 
were in the size range of 1 to 4 µm and were composed of agglomerated drug nanoparticles 
approximately 200 nm in size.  The micronized stock drugs were approximately 2 to 10 µm for 
both budesonide and danazol and were solid crystals.  MFI confirmed that the typical median 
size or D50 of the NanoClusters was between 1 and 2 microns and decreased with milling time.  
The micronized stock was over 2 microns in size, slightly larger than both budesonide and 
danazol NanoClusters (Table 2.1 and 2.2).  Samples were tested over a period of two years 
with a negligible change in particle size in both DLS and MFI to confirm physical stability (Table 



























Figure 2.1: SEM images of A) micronized stock budesonide, B) NanoCluster powder milled for 
5 hours, C) NanoCluster powder milled for 10 hours, D) NanoCluster powder milled for 15 
hours, E) nanoparticle suspension powder milled in 0.1% (w/v) Pluronic® F-68 solution.  


























Figure 2.2: SEM images of A) micronized stock danazol, B) NanoCluster powder milled for 5 
hours, C) NanoCluster powder milled for 10 hours, D) NanoCluster powder milled for 15 hours, 
E) nanoparticle suspension powder milled in 0.1% (w/v) Pluronic® F-68 solution,  Magnification 
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Table 2.1: Budesonide Powder Characteristics (*Calculated from BET; **Calculated 
from particle size46). Particle size was determined using DLS while MFI was used to 





































15 Hour Milled 0.88±0.08% 
420.7±11.




















Table 2.2: Danazol Powder Characteristics (*Calculated from BET; **Calculated from 
particle size46).  Particle size was determined using DLS while MFI was used to 
































































The NanoClusters had a different particle morphology compared to the other samples 
(Fig 2.1B-D and 2.2B-D).  The NanoClusters were somewhat spherical or irregular 
microparticles formed by agglomerated 200 – 400 nm nanoparticles with some cavities and 
voids left between the nanoparticles.  The nanoparticle suspension samples were mostly 
individual nanoparticles stabilized by Pluronic® F-68 during synthesis (Fig 2.1E and 2.2E).  
Small agglomerates in the nanoparticle sample formed as a result of the drying process during 
lyophilization. The nanoparticle suspension samples had particle distribution mainly below 1 µm 
with a mean size of 250 nm with some reversible agglomeration occurring after lyophilization.   
After an initial period of size reduction, the particles in the agglomerated NanoClusters 
slightly increased in size by approximately 70 nm with increasing milling time (Table 2.1 and 
2.2).  There are a couple of possible explanations for this increase in particle size.  One would 
be that even though the agglomerates are sonicated in 0.1% (w/v) Pluronic® F-68 for sizing, the 
individual particles are still partially agglomerated together due to high surface energy.  
Individual particles are not being measured, just smaller agglomerates27.  It is important to note 
that without the sonication step, the NanoClusters remained as agglomerated nanoparticles 
above the limits of DLS.  Even in a dilute surfactant solution, the NanoClusters need to be 
subjected to intense ‘shear’ (sonication) to disrupt the agglomerated microparticles to generate 
the individual nanoparticles.  Another less likely explanation is the crystals of the drug are 
fractured to generate the decreased particle size, and over time crystal healing or Ostwald 
ripening occurs increasing the particle size9,27.  This hypothesis was not supported, however, by 
SEM observations.  SEM micrographs do give information about the morphology of the 
NanoClusters.  The NanoClusters have voids between the nanoparticles (Fig 2.1 and 2.2), due 
to the agglomeration process which forms the particles.  These voids are part of the reason for 




2.3.2. Increase in Surface Area and Not a Change in Drug Properties Enhanced 
Dissolution 
 The increased dissolution rate was a direct result of the increase in surface area of the 
NanoCluster samples.  The micronized stock materials had surface areas around 3 to 4 m2/g, 
while the NanoCluster samples had surface areas of 8 times more for budesonide and even 10 
to 15 times more for danazol (Table 2.1 and 2.2).  There was no discernible trend for the 
increased surface area for budesonide as the milled NanoCluster samples all had approximately 
33 m2/g (Table 2.1).  Danazol, however, showed a considerable trend with longer mill times.  
There was an increase of approximately 11 m2/g for each 5 hour increase in mill time (Table 
2.2) corresponding to an 8, 11, and 14 fold increase for the NanoCluster samples milled for 5, 
10, and 15 hours, respectively.   
The nanoparticle suspension for both compounds when run through BET surface area 
analysis gave a measured value of approximately 10 m2/g.  This value does not agree with the 
surface area of 35 m2/g calculated from measured particle hydrodynamic radius suggesting that 
the Pluronic® stabilizer may have caused an anomalous reading.  Comparing the calculated 
value with the milled NanoCluster samples shows that the surface area of the nanoparticle 
samples would match the respective budesonide NanoCluster samples and the 10 hour milled 
danazol NanoCluster sample.  A calculation of nanoparticle suspension surface area (from 
dissolution data) is similar to the surface area of NanoClusters determined by BET (Table 2.1 
and 2.2), which also supports the similar dissolution kinetics observed47.   
The increase in surface area would account for the increase in dissolution, but there 
were some observed differences in the trends.  For budesonide, the surface area of all the 
milled NanoCluster samples and the nanoparticle suspension, were similar yet there were some 
small differences in the dissolution profiles.  For danazol, there was a marketed difference in 
surface area between the milled NanoCluster samples, yet there was no discernible difference 
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in the dissolution profiles.  It is possible that attaining a ‘threshold’ surface area is important. In 
other words, increasing surface area by at least 7 times compared to the micronized stock 
diminishes differences for these particular drugs as the surface area is further increased.  
Another explanation could be local saturation.  After a 7 to 8 fold increase in surface area, 
dissolution may not increase due to a lack of local sink conditions (i.e. within the NanoCluster) 
or some other factor specific to these two compounds.  As mentioned before, concentration 
gradients from the surface of the individual nanoparticles may impinge (darker regions in Fig 
2.12 as dissolution profiles overlap) yielding a more complicated dissolution profile than 
predicted by changes in surface area alone30.  An enhancement would still be seen in 
dissolution, but that enhancement may not be as extensive as expected.  Finally, it is also 
possible that these two compounds may not exhibit a strict surface area correlation43.  
 HPLC-UV analysis of NanoClusters showed that there was relatively little degradation 
even at extended milling times (Table 2.1 and 2.2)43.  The percent degradation increased from 
0.18% to 0.81% for budesonide and 0.21% to 1.29% for danazol as milling time progressed 
from 5 – 15 hours.  The degradation products were determined by comparing the HPLC curves 
of the micronized stock and the milled products (Fig 2.3 and 2.4).  Peaks were clearly separated 
allowing use of this approach.  Previous literature results suggest the expected degradant 
products for budesonide to include 16α-hydroxyprednisolone and 6β-hydroxybudesonide36 and 
for danazol ethisterone and 2-hydroxymethyl ethisterone37.  These compounds are formed as 
hydrophobic portions of the parent compound are removed thereby decreasing hydrophobicity.  
The removal of these hydrophobic regions increases the exposure of more polar heteroatoms.  
These two chemical differences explain why the new peaks associated with degradation 














Figure 2.3: Chromatogram of budesonide. The gray trace shows the 10 hour milled 
NanoCluster chromatogram while the black trace shows the micronized stock form.  The inset is 





















Figure 2.4: Chromatogram of danazol. The gray trace shows the 10 hour milled NanoCluster 
chromatogram while the black trace shows the micronized stock form.  The inset is the 
chromatogram portion from the black box magnified to illustrate the degradant peak.   
 
 DSC thermograms illustrate the samples maintained the same relative crystallinity43.  A 
decrease was seen in the melting temperature of both danazol and budesonide NanoCluster 
samples compared to the micronized stock material (Table 2.1 and 2.2).  A decrease in melting 
temperature is commonly observed as particle size decreases.  Since the NanoCluster samples 
are composed of nanoparticle agglomerates and each agglomerated microparticle has multiple 
crystals, heat is transported quickly in individual nanoparticles resulting in the decreased melting 
temperature as milling time increased.  The nanoparticle powders also had decreased melting 
temperatures compared to the micronized stock material and had a similar melting temperature 
to the NanoCluster samples milled for 5 hours.  The fact that the nanoparticle powder had a 




milled for a short time is further evidence that the samples have not changed crystalline form to 
either an amorphous solid or different polymorph.  The shape of the DSC curves provided 
further evidence as well.  The curves have a very definitive and sharp peak expected for 














Figure 2.5: DSC of budesonide.  Black solid line is the micronized stock budesonide, gray 
solid line is NanoCluster milled for 5 hours, gray short dash line is NanoCluster milled for 10 
hours, gray long dash line is NanoCluster milled for 15 hours, and the black dash line is the 
nanoparticle suspension powder milled in 0.1% (w/v) Pluronic® F-68 solution. 
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Figure 2.6: DSC of danazol.  Black solid line is the micronized stock danazol, gray solid line is 
NanoCluster milled for 5 hours, the black dash line is the nanoparticle suspension powder milled 
in 0.1% (w/v) Pluronic® F-68 solution, gray short dash line is NanoCluster milled for 10 hours, 
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The PXRD data complements the DSC data and lends further credence to the idea that 
there was no change in crystallinity that caused the increase in dissolution rate (Fig 2.7 and 
2.8)43.  For budesonide, there was a decrease in peak intensity of the NanoCluster samples 
compared to the micronized stock budesonide.  There was a small decrease in resolution from 
the micronized material as well compared to the NanoClusters, but the NanoClusters had a 
higher peak intensity compared to the nanoparticle sample.  There was no trend in peak 
intensity that correlated to increases in mill time for the budesonide NanoClusters.  The 
decrease in peak intensity seen particularly in Fig 2.8 can potentially be due to the nanosizing of 
the drug crystals.  Nanosizing can produce differences in the xray scattering so the 
agglomerated particles can have subtle differences in scattering that may decrease intensity but 
peak position is more determinant.  Differences due to nanosizing were also seen in the DSC 
thermograms, which provide further evidence that the decrease in signal intensity was not due 
to a change from crystalline to amorphous.  
The danazol samples had a slight difference from the budesonide samples.  Similar to 
budesonide, the micronized danazol sample had a higher peak intensity and resolution as 
compared to the NanoClusters.  The peak height in danazol NanoCluster samples did appear to 
decrease in intensity with increased mill time.  The 5 hour milled NanoCluster sample had a 
higher intensity than the nanoparticle suspension sample but the 10 hour and 15 hour milled 
samples had a lower peak intensity on average.   
 There was an interesting repeating theme as the nanoparticle samples had very similar 
properties to the 5 hour milled NanoCluster samples or between the 5 and 10 hour milled 
NanoCluster samples.  For example, even though the nanoparticle samples were milled for less 
than half the time of the 5 hour milled NanoCluster sample, all the samples had similar melting 
temperatures and PXRD patterns for both budesonide and danazol.  Practically speaking, 
















Figure 2.7: PXRD of budesonide.  Micronized budesonide is the top trace followed by 5 hour 
milled NanoCluster, 10 hour milled NanoCluster, 15 hour milled NanoCluster, and nanoparticle 
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Figure 2.8: PXRD of danazol.  Micronized danazol is the top trace followed by 5 hour milled 
NanoCluster, 10 hour milled NanoCluster, 15 hour milled NanoCluster, and nanoparticle 
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2.3.3. NanoClusters Enhanced Dissolution Rate 
 NanoCluster samples had increased dissolution rates as compared to the micronized 
stock drugs (Fig 2.9 and 2.10).  Both budesonide and danazol micronized material gradually 
dissolved over the one hour study.   Approximately 55% to 70% of the micronized drugs were 
dissolved in the first 5 minutes.  Micronized budesonide and danazol samples required 
approximately 30 and 45 minutes, respectively, to dissolve completely.  The nanoparticle 
suspension powder almost instantaneously dissolved and maintained a constant level over the 
course of the one hour study for both drugs. The NanoCluster samples had dissolution kinetics 
in between the two controls but were statistically more similar to the nanoparticle suspensions.   
 
Figure 2.9: Dissolution of budesonide. Diamonds show the micronized stock while the 
dark squares, triangles and light squares show the NanoCluster powder milled for 5, 10, 
and 15 hours respectively.  The circles represent the nanoparticle sample.  All error 
bars are the standard deviations of 3 runs.  Stars denote a P value < 0.05 between the 






























Figure 2.10: Dissolution of danazol.  Diamonds show the micronized stock while the 
dark squares, triangles and light squares show the NanoCluster powder milled for 5, 10, 
and 15 hours respectively.  The circles represent the nanoparticle sample.  All error 
bars are the standard deviations of 3 runs.  Stars denote a P value < 0.05 between the 



































For budesonide, there appeared to be a minor correlation between NanoCluster milling 
time and dissolution rate.  The NanoCluster sample milled for 5 hours appeared to have less 
drug dissolved in the first 15 minutes compared to the NanoCluster sample milled for 10 hours, 
which was lower than the NanoCluster sample milled for 15 hours by a similar margin.  
Differences in these dissolution rates, however, were not statistically significant according to a 
paired T-test. NanoCluster samples milled for 15 hours had a higher dissolution rate than 5 hour 
milled NanoClusters up to 30 minutes.  For danazol, there did not appear to be any differences 
between the milled NanoCluster samples.  There was a small gradual increase (about 10%) in 
concentration with the NanoCluster samples milled for 10 and 15 hours showing a similar trend 
to the increase seen in comparison to the micronized stock.  These differences again were not 
significant.  Overall, the NanoCluster samples had faster dissolution rates compared to the 
micronized stock and similar to the nanoparticle suspension, but differences between the 
different NanoCluster mill times were not significant. 
The next step was to model the dissolution profiles to see if they followed any previous 
models (Table 2.3 and Fig 2.11).  The Higuchi model is the classical standard and follows a √𝑡 
dissolution model as seen in Eqn 2.1, but it was originally developed to describe the transport 
from a thin film into the skin.  The Higuchi model is a macroscopic model that does not apply to 
our microscopic system and does not have the same geometry as our system.  Thus the 





Figure 2.11: Dissolution models to represent micronized stock and NanoCluster 
dissolution profiles.  Four models are included – two macroscopic models (Higuchi and 
Late Time Approximation) and two microscopic models (Micronized Drug and 
NanoCrystal® Drug).  The two microscopic models better represent the data. 
 
Further refinements of the Higuchi dissolution model were made by Peppas, who 
included multiple geometries including spheres and cylinders as drug release systems.  Peppas 
solved for the dissolution from a sphere (Eqn 2.3)42.  This equation was developed for tablets 
and formulations on a macroscopic scale, and when applied to the microparticles or 
nanoparticles used here, fails in part due to the smaller scale and irregular surface area of the 































was developed to describe release from several different drug carrier systems including drug 
reservoirs, monolithic solutions, or monolithic dispersions.  The monolithic solution, which more 
closely resembles our NanoClusters samples as it is a sphere of homogenously dispersed drug 
with no exterior coating.  The full model is the same as the system developed by Peppas (Eqn 
2.3).  The Siepmann model, however, provides a short time (less than 40% of drug released – 
Eqn 2.4) and a late time (more than 60% of drug released – Eqn 2.6) approximation for drug 
release.  Again, using this model of late time approximation as the lowest amount of drug 
measured was 57% released, did not properly model NanoCluster dissolution kinetics.  The 
major issue with this model, as with the previous two, is that this model targets macroscopic 
systems such as a tablet or capsule containing drug.  As the system becomes smaller for micro 
and nanoparticles, the decreased radius skews the equations leading to inaccurate results42.  In 
Fig 2.11, the Siepmann model is shown to have a good fit but that requires falsely inflating of 
the size of the particle, increasing it by 1000 fold to achieve this close fit. 
Other models offer a better fit that can provide further explanation of this data.  There 
are several models with NanoCrystal® technology which is similar to the nanoparticle 
suspension.  A model based on two different processing methods: jet milled and NanoCrystal® 
was previously reported45.  The reported jet milled product is very similar to the micronized stock 
used here with a median particle size of 3 µm and a distribution where 90% of the product is 
between 2 – 10 µm.  The jet milled product has a similar size range as well to our milled 
NanoCluster providing a reasonable starting point to model dissolution of both the micronized 
stock and NanoClusters.  The reported NanoCrystal® model has almost constant dissolution 
throughout time in the model.  The difference in surface areas between the jet milled and 
NanoCrystal® was 8-9 fold.  The jet milled model very closely traces our micronized stock 
profile with a slight overestimation but stays within 5% throughout the length of the study and 
model.   
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The more interesting observation occurs with the milled NanoClusters. Even though the 
NanoClusters have a similar geometric size to the jet milled product they have a similar 
dissolution profile to NanoCrystal® throughout most of the model.  The NanoClusters have a 
similar increase in surface area compared to the micronized stock when contrasting the 
reported modeling of NanoCrystal® compared to the jet milled product.  The only difference is in 

















Table 2.3: Dissolution models and governing equations  












𝑘 = 𝐴√2𝐶𝑖𝐷𝐶𝑠 
 
Eqn 2.2 
Ci = initial 
concentration 
Cs = drug 
solubility 
A = surface 
area 
D = diffusion 
coefficient 
t = time 
Mt = released 
drug 
1. Thin polymer 
film 
2. Constant D 
3. Minimal edge 
effects 







































a = radius of 
sphere 
D = diffusion 
coefficient 
t = time 





Mt = released 
drug 
1. Constant D 





4. Short term 
approx. only for 












































Ci = initial 
concentration 
Cs = drug 
solubility  
a = radius of 
sphere 
D = diffusion 
coefficient 
R = radius of 
sphere 
t = time 




2. Constant D 
3. Drug 
transport in 




5. Late time 






One cause that could be simply not enough data points were collected during the early 
time phase (the first ten minutes).  Another factor could be the NanoCluster microenvironment 
as illustrated in Fig 2.12.  With the micronized stock and nanoparticle suspension, there may be 
well defined water contact with the free surface of drug particles allowing an approximation that 
sink conditions are maintained at all free surfaces.  Because sink conditions can be maintained, 
the concentration profiles in gray are maintained allowing for simple modeling of dissolution 
from the particle surface (Fig 2.12A and 2.12C).  Since NanoClusters are comprised of 
agglomerated nanoparticles, the space between the nanoparticles could experience a high local 
concentration that approaches or exceeds saturation.  Due to the interplay of dissolution from 
adjacent surfaces, local concentration gradients could be affected.  This complexity is difficult to 
model and may help explain the differences seen in the early time frame.  As the particles 
continue to dissolve, the particles shrink providing a larger space between the individual 
particles thus reducing the impact of impinging concentration profiles allowing the model to 

























Figure 2.12: Models in black of A) micronized stock drug, B) milled NanoCluster, and C) 
nanoparticle suspension.  Grey represents dissolution gradients from particles.  
Micronized stock in A and nanoparticle suspension in C have well defined concentration 
profiles.  NanoCluster sample in B shows in the inset (enlargement of the three starred 
particles) that due to the individual particles proximity, the concentration gradient can 










































 Corticosteroids are the standard treatment for asthma, but there are several challenges 
with their formulations.  DPI formulations are gaining in popularity but have their own delivery 
difficulties associated with particle size deposition and delivering the formulation to the lung, as 
typically only 20% enters into the lung.  Multiple particle engineering strategies have been 
employed to address these issues including wet milling, which was utilized to create 
nanoparticle agglomerates called NanoClusters.  By increasing the dissolution rate of these 
typically poorly water soluble compounds, they are more likely to enter solution before they can 
be cleared by any of the multiple transport mechanisms in the lungs.  NanoClusters yielded 
faster and more complete dissolution compared to micronized drug and had dissolution kinetics 
similar to nanoparticle suspension samples.  The increased dissolution kinetics was theorized to 
be from an increase in surface area and not due to a change in crystalline form as 
demonstrated by DSC and PXRD analysis.  By processing poorly water soluble drugs into 
NanoClusters, increased dissolution kinetics can be achieved using these high surface area 
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Hyaluronic Acid Molecular Weight 
Determines Lung Clearance and 









Hyaluronic acid (HA), is a linear biopolymer component of multiple approved products 
and exhibits versatility for drug delivery, since it is available in a wide range of molecular 
weights and offers multiple sites for chemical modification1-6.  In the human body, HA is 
prevalent in cartilage, skin, and synovial fluid and is typically present as a very high molecular 
weight (up to 20 MDa) polymer, providing elasticity to tissues.  As HA degrades, it drains away 
from these tissues, percolating with interstitial fluid into and through lymph nodes with a portion 
passing into the systemic circulation7-13.  Thus, HA serves as an interesting polymer to carry 
drugs.  Absorption of HA after subcutaneous14-18 , intraperitoneal19, oral20,21, and intravenous 
injection22-24 has been reported, but the fate of HA after pulmonary administration is not well 
understood.  Recent work suggesting HA may be useful for inhaled drug delivery motivates a 
better understanding of HA fate after pulmonary administration25-29.   
The lungs eliminate materials using active transport processes including mucociliary and 
macrophage clearance, as well as passive diffusion to the bloodstream or lymph30.  Mucociliary 
clearance occurs in the upper airways as ciliated cells sweep mucus up the trachea and into the 
oropharyngeal cavity where it is typically swallowed.  HA residence time in the upper airways, 
therefore, depends on the distance from the site of deposition to the oropharyngeal cavity.  The 
rate of mucociliary clearance can also depend on mucus viscosity.  Slower and/or incomplete 
clearance of thick mucus is observed clinically while expectorants facilitate better mucus 
clearance.  Further down the airways in the terminal bronchioles and alveoli, macrophages can 
recognize molecules or particles.  Macrophages that have bound or phagocytosed HA can then 
actively traffic to the lymphatics draining the pulmonary bed.  Finally, HA molecules may 
dissolve into the fluid layer lining the lung epithelium and then passively diffuse into the 
bloodstream30-33.  This mode of systemic absorption is usually fastest in the alveolar region, 
where the tissue barriers are as thin as a few hundred nanometers32,34.  Passive diffusion into 
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the lymphatic network draining the lungs may also be possible, although this clearance 
mechanism might be expected to be slower compared to absorption into the bloodstream30, 32, 33.   
In general, endogenous HA present in tissues has several different elimination routes as 
it is degraded to lower molecular weight chains through enzymatic and non-enzymatic 
mechanisms7-13.  Endogenous HA that is part of the extracellular matrix or synovial fluid is on 
the order of 4-20 MDa in size.  Enzymatic reactions that degrade HA occur in the interstitial 
space, in lymph, or in the blood by enzymes such as hyaluronidase.  Non-enzymatic 
degradation of HA can occur by non-specific chemical reactions including acidic or alkaline 
hydrolysis or oxidation.  These degradation pathways yield smaller HA fragments (100s of kDa 
in size), which then drain with interstitial fluid7-13.   
The interstitial fluid is collected into the lymphatics, where the majority of HA fragments 
smaller than 450 kDa are removed from the lymph fluid during filtration through lymph nodes 
before the fluid is passed back into the blood35,36.  These HA fragments are then further 
degraded into even smaller fragments in the lymph nodes since the majority of HA turnover 
occurs in the lymphatics, thereby eliminating the HA fragments before they enter the blood 
circulation6-8.  Lymphatic drainage of HA can be facilitated by active transport by binding to 
CD44 expressed on the surface of macrophages or lymphocytes37,38.  Some HA fragments can 
reach systemic circulation from the interstitial fluid.  In the blood, larger HA fragments (hundreds 
of kDa in size), circulate until reaching the liver where endothelial cells remove HA from 
circulation5,39,40.  HA plasma clearance is rapid (half-life as low as 2 minutes)22.  Alternatively, 
smaller molecular weight HA fragments can be eliminated by the kidneys since where the 
molecular weight cut off for efficient urinary excretion is approximately 25 kDa4,5,22. 
The lungs offer a route of administration that can facilitate local therapy, access to 
systemic circulation, and perhaps even delivery to pulmonary lymph nodes.  HA is likely to be 
well-tolerated in the lungs as evidenced by studies where HA has been delivered by inhalation 
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to dogs41 or nebulized into humans to treat lung inflammation25-29.  In addition, HA is emerging 
as an important carrier molecule for drug delivery.  In the present study, HAs of discrete 
molecular weights were administered to the lungs of mice via intratracheal instillation to 
determine how HA molecular weight dictates persistence in the lung, systemic absorption, and 
access to lymph nodes draining the pulmonary bed.  HA molecular weights, of 7, 30, 67, 215, 
and 741 kDa were studied, and biodistribution was assessed by using fluorescent or 
radiolabeled HA3,42-44.    
 
3.2. Materials and Methods 
3.2.1. Materials 
The different molecular weights (7.5, 29/31, 67, 215, and 741 kDa) of hyaluronic acid 
(HA) were obtained from Lifecore Biomedical (Chaska, Minnesota).  The 29/31 kDa HA (herein 
referred to as 30 kDa HA) was received in two different lots, with average molecular weights of 
29 kDa and 31 kDa.  The near infrared dye, HiLyte FluorTM 750 hydrazide, was obtained from 
AnaSpec (Fremont, California).  DMTMM  
(4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride) was obtained from 
ChemPep Inc (Wellington, Florida).  Pierce iodination beads were purchased from Thermo 
Scientific (Rockport, Illinois) and Na125I from PerkinElmer (Waltham, Massachusetts).  The 
mouse laryngoscope was obtained from Penn-Century (Wyndmoor, Pennsylvania).  All water 
used was deionized (DI) water from a Labconco Pro PS system.  All other chemicals and 
materials including tyrosine, EDC (1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide), 3500 Da, 
20000 Da, and 50000 Da molecular weight cutoff dialysis tubing, PD-10 columns, bent fine 
dissecting forceps, glacial acetic acid, sodium acetate, sodium phosphate monobasic 
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monohydrate, sodium phosphate dibasic, Fisherbrand disposable culture tubes (12x75mm), and 
phosphate buffered saline were purchased from Fisher Scientific (Pittsburgh, Pennsylvania). 
 
3.2.2. Near Infrared Dye labeling of HA  
A 1 mg vial of HiLyte Fluor 750 hydrazide dye was dissolved in 1 mL of 50 mM acetate 
buffer, pH 5.0.  HA (7.5 mg) was dissolved in 4 mL of 50 mM acetate buffer, pH 5.0, with 0.5 
equivalents of EDC to which the 1 mg/mL of dye was added2,44-49.  The reaction was allowed to 
proceed for approximately 16 hours at room temperature and stirred at 450 rpm protected from 
light.  After 16 hours, the reaction mixture was dialyzed using 3500 Da molecular weight cutoff 
dialysis tubing for 7.5 kDa HA, 20000 Da molecular weight cutoff dialysis tubing for 30 kDa HA, 
and 50000 Da molecular weight cutoff dialysis tubing for 67, 215, and 741 kDa HA; the dialysate 
was replaced every 6 hours for 24 hours.  The HA-IR dye conjugate was removed from the 
tubing and then frozen at -20°C.  Samples were lyophilized for 72 hours at a temperature of -72 
°C at a vacuum of <300 millitorr (VirTis Feezemobile-12XL, The Virtis Company, NY).  Samples 
were reconstituted using DI water to a concentration of 1 mg/mL prior to instillation. 
Conjugation of the dye to HA was confirmed using HPLC (Figure 3.1).  The conjugation 
efficiency of the dye was determined by taking a sample of the reaction mixture and comparing 
the intensity of the fluorescent peak before and after dialysis.  The HPLC-fluorescence system 
consisted of a Shimadzu CBM-20A system controller, a LC-20SB solvent delivery pump, a RF-
10A XL Shimadzu Fluorescent detector, and a SIL-20 AC HT autosampler (Shimadzu Corp, 
Kyoto, Japan).  Chromatograms were acquired and analyzed using LC Solutions software.  An 
isocratic system with a mobile phase of 50 mM acetic acid, pH 5.0, was used with a Vydac 
HPLC protein and peptide C18 column (5 µm particles, 4.6 mm x 250 mm).  The flow rate was 
0.5 mL/min, the injection volume was 20 µL, and the excitation and emission wavelengths were 
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753/782 nm respectively.  The HA samples were diluted to a concentration of approximately 1 






















Figure 3.1: Depiction of full HA monomer unit, abbreviated HA, DMTMM molecule, and IR dye 
as a hydrazine group.  A shows chemical reaction of HA with DMTMM and tyrosine for tyrosine 
conjugation followed by addition of 125I for radiolabeled HA.  B shows hydrazine IR dye reaction 
leading to conjugation on HA. 
 












3.2.3. Radiolabeling of HA 
For radiolabeling of HA, 60 mg HA was dissolved in 3 mL of 1 mM phosphate buffer pH 
6.0 with 13.5 mg of tyrosine (0.5 equivalents).  The pH was adjusted back to 6.0 using 1.0 M 
HCl after which 20.7 mg of DMTMM was added (0.5 equivalents).  The reaction mixture was 
stirred at 175 rpm for approximately 16 hours at room temperature.  Afterwards, samples were 
dialyzed, lyophilized, and reconstituted as necessary as described previously3,24,42-44,50-52. 
Conjugation of tyrosine to HA was confirmed by 1D proton NMR.  The NMR was run 
using a scan rate of 16 scans and 2 dummy scans using deuterium oxide as the solvent at a 
concentration of 10 mg/mL.  The NMR was a 400 MHz Bruker (Billerica, MA) AV spectrometer 
equipped with a X-channel observe probe.  Conjugation efficiency was calculated by comparing 
the integration of HA peaks to the integration of tyrosine peaks.  The conjugation efficiency of 
tyrosine to 741 kDa HA was unable to be determined due to viscosity issues limiting the 
concentration of the sample.   
Iodine labeling was performed using iodination beads (Figure 3.1).  Two iodination 
beads were used per HA molecular weight sample and were rinsed with 10X PBS for 3 minutes.  
The beads were then dried on filter paper and added to 200 µL of Na125I (1 mCi) in 10X PBS 
and incubated for 5 minutes at room temperature.  HA-tyrosine (150 µL of 1 mg/mL) was added 
to the Na125I and bead solution was incubated overnight at room temperature.  The reaction 
mixture was then transferred to an equilibrated PD-10 column.  To elute the HA-125I, 6 mL of 
PBS was added, and 500 µL fractions were collected in Eppendorf tubes.  From each fraction, 
10 µL was taken and transferred to a new Eppendorf tube and counted using a Canberra model 
2000 NIM BIN with Canberra model 802-4W NaI Well (3” by 3” well) detector gamma counter.  
The amplifier was a Canberra model 814A with a Ortec model 775 counter, Ortec model 719 
timer, Ortec model 495 power supply, and a Canberra model 2030 single channel analyzer 
(SCA).  The settings used were an amplifier coarse gain of 8 and fine gain of 8.8 with the power 
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supply set at 875, SCA of Delta E: 10 and a lower level discriminator of 0.06.  To determine 
conjugation efficiency of 125I to HA-tyrosine, an ethanol precipitation method was used.  The 
highest intensity vial from the 10 µL aliquot of HA-tyrosine-125I (from now on HA-125I) PD-10 
eluents had 20 µL of 20 mg/mL HA added followed by the addition of 200 µL of cold ethanol.  
The mixture was put on dry ice for 20 minutes then was centrifuged at 2000 rpm for 20 minutes 
on a Biofuge A centrifuge by American Scientific Products.  The supernatant was then 
separated from the pellet and both were recounted on the scintillation counter.  Eqn. 3.1 was 
used to determine the conjugation efficiency from the scintillation data.  All radiolabeling was 
conducted under the supervision of the University of Kansas Radiation Safety Committee. 
𝐸𝑞𝑛 3.1:     
𝑃𝑒𝑙𝑙𝑒𝑡 𝑅𝑎𝑑𝑖𝑜𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (𝑐𝑝𝑚)
𝑃𝑒𝑙𝑙𝑒𝑡 𝑅𝑎𝑑𝑖𝑜𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (𝑐𝑝𝑚) + 𝑆𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡 𝑅𝑎𝑑𝑖𝑜𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (𝑐𝑝𝑚)
∗ 100% 
 To prepare the HA-125I for intratracheal instillation, a similar ethanol precipitation 
procedure was used.  Approximately 22-25 mg of HA was dissolved in 500 µL of water then a 
500 µL fraction of HA-125I collected from the PD-10 column was added.  The HA-125I / HA 
solution was precipitated with approximately 12 mL of cold ethanol and after sitting on dry ice for 
10 minutes, the sample was centrifuged for 10 minutes at 12000 rpm using a Dynac 2 centrifuge 
from Becton Dickinson.  The supernatant was removed and the pellet was dissolved in 2 mL of 
DI water (for HAs <700 kDa) or 3 mL of DI water for the 741 kDa HA.   
 
3.2.4. Sizing of HA 
Size exclusion chromatography (SEC) was employed to determine the difference in 
molecular weight between HA and HA-tyrosine.  Samples were analyzed at a concentration of 5 
mg/mL.  The system used was a Waters e2695 separation module, Waters 2414 refractive 
index detector, and Waters 2489 UV/Vis detector with two columns in series: a PL Aquagel-OH 
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60 Analytical SEC (300 x 7.5 mm) then a PL Aquagel-OH 40 Analytical SEC (300 x 7.5 mm) 
(Santa Clara, California).  Samples (80 µL of 5 mg/mL) were dissolved and run using an 
isocratic 0.5 mL/min mobile phase of 0.1 M ammonium acetate with 0.136 M sodium chloride at 
pH 5.  Chromatograms were analyzed using EMPower 3. 
Dynamic light scattering (DLS) of HA was executed to determine the approximate 
physical size of the HA in solution.  DLS was performed using a ZetaPALS (Brookhaven 
Instruments Corp., ZetaPALS, Holtsville, NY).  HA was dissolved in 1X PBS at a concentration 
of 1 mg/mL and filtered through a 0.45 µm filter.  Measurements were performed in a glass 
cuvette using ZetaPALS software (Holtsville, NY). 
 
3.2.5. Animals  
 BALB/C mice (female, 4 weeks old at 13 – 16 grams) were supplied by Monash Animal 
Research Services (Victoria, Australia) for the near infrared dye imaging and by Harlan 
Laboratories (Indianapolis, IN) for the radiolabeling.  One group of Harlan mice were used in a 
crossover study of near infrared dye imaging to confirm similar pharmacokinetic behavior 
between the different suppliers.  Mice were maintained on a 12 hour light/dark cycle and were 
fed standard rodent pellets with no dietary restrictions nor withheld food.  Water was freely 
available at all times.  All animal experiments were approved by the Monash Institute of 







3.2.6. Intratracheal Instillation of HA  
 For lung administration via intratracheal instillation, each animal was anesthetized with 
2% isoflurane in an induction chamber for approximately 4 minutes.  The unconscious mouse 
was positioned in dorsal recumbency using a dosing board at approximately 60° to a supine 
position suspended by incisor teeth using a thin wire.  A nose cone was used to maintain 
anesthesia53.  The mouth was opened and the tongue was gently pulled out and to the side of 
the mouth.  A laryngoscope was then positioned to depress the tongue and visualize the vocal 
cords at the top of the trachea.  A 50 µL solution of labeled HA was then pipetted at the top of 
the trachea.  The tongue was withheld for at least 3 breaths, after which time the mouse was 
maintained under anesthesia for an additional 3 minutes on the dosing board.  The mouse was 
then removed from the dosing board and allowed to recover from the anesthesia by being held 
vertically until movement was regained.  For the near infrared dye, 1 mg/mL of HA-IR dye was 
instilled and for the radiolabeled HA, approximately 11-12 mg/mL HA for 7, 30, and 67 kDa HA, 
2.8 mg/mL for 215 kDa HA and 1.6 mg/mL for 741 kDa HA was instilled according to Table 3.1. 
 
3.2.7. Near Infrared Dye Ex Vivo Imaging  
At 1, 8, or 24 hours after intratracheal instillation, mice were euthanized via an i.p. 
injection of sodium pentobarbital (>100 mg/kg body weight), and death was confirmed by the 
absence of a heartbeat.  The lungs, trachea, heart, spleen, liver, kidney, stomach, intestine, and 
bladder were then excised to evaluate the relative distribution of HA in mice at the different time 
points.  Fluorescent images were collected on a Caliper life sciences IVIS Lumina II from 
Thermo Fisher Sciences (Victoria, Australia) using living image V 4.3.1 software from Caliper 
Life Sciences, Massachusetts.  A 745 nm wavelength bandpass filter was used for excitation 
and 780 nm as the emission filter.  All points included at least 3 mice.  Fluorescent images that 
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were repeated and collected at the University of Kansas were performed on a Cambridge 
Research and Instrumentation Maestro multi-spectrum imager (Woburn, Massachusetts) with 
an excitation filter of 710–760 nm and long pass emission filter of 800–950 nm. 
 
 
3.2.8. Counting of Signal from Radiolabeled Tissue  
 At 1, 2, 4, 6, and 8 hours after intratracheal instillation, mice were euthanized via 
isoflurane overdose in an inhalation chamber in a hood and death was confirmed by cessation 
of breathing for 5 minutes.  The tissues of interest were then surgically removed including the 
right axillary and brachial lymph nodes, the left axillary and brachial lymph nodes, trachea, 
heart, right and left lung lobes, spleen, liver, stomach, intestine, kidneys, bladder, and final fecal 
pellet in the GI tract.  Each tissue sample was suspended in approximately 2-3 mL of 1X PBS in 
12 by 75 mm glass Fisherbrand tubes.  Samples were scintillated on a Beckman Gamma 5500B 
system with a 3” by 3” NaI detector.  Counts were taken for 1 minute, and the average of 3 or 
more readings was used.  All bladders were assayed without urine to keep the measurements 
consistent.  Samples were corrected for dose and radiolabeling efficiencies.  All time points for 
all test articles exhibited <5% error for the measurement except for the intestine 7 kDa HA at 1 
hour and 741 kDa at 1 and 2 hours. 
 
3.2.9. PK Analysis of Radiolabeled Tissue  
 Pharmacokinetic (PK) analysis of the radiolabeled HA data was performed using 
WinNonlin 6.3 software.  Non-compartmental modeling analysis was performed assuming first 
order input with uniform weighing using extravascular dosing, plasma type model for tracking, 




3.3.1. Size Characterization of HA  
 The selection of the molecular weights of HA (7, 30, 67, 215, and 741 kDa) provided a 
size range representative of endogenous median to low molecular weight HA with regular size 
intervals.  Theoretical radii of gyration and theoretical hydrodynamic radii were calculated 
utilizing Eqn 3.2 and Eqn 3.3 respectively54,55.   Theoretical radii of gyration ranged from 7 nm to 
100 nm across the molecular weights of HA studied and theoretical hydrodynamic radii ranged 
from 3 nm to 54 nm (Table 3.1).   
𝐸𝑞𝑛 3.2: 𝑅𝑔 = 2.35 [𝑀𝑊 𝑖𝑛 𝑘𝐷𝑎]0.57              𝐸𝑞𝑛 3.3:  𝑅ℎ = 0.87[𝑀𝑊 𝑖𝑛 𝑘𝐷𝑎]0.63 
 DLS was performed on the different molecular weights of HA to compare the measured 
hydrodynamic radii of HA molecules to the calculated values.  As expected, the measured size 
increased with molecular weight (Table 3.1).  The size of HA increased from 6 to 55 nm, which 
corresponded relatively well to the theoretical estimates of the radius of gyration and 
hydrodynamic radius.   
 


























7 7.1 3.0 6.1 ± 0.2 14 ± 3 13 ± 2 14.8 
30* 16.3 7.4 12.2 ± 1.3 68 ± 7 59 ± 4 68.9 
67 25.8 12.3 22.1 ± 1.2 155 ± 14 127 ± 9 161.0 
215 50.2 25.6 33.3 ± 0.2 557 ± 28 435 ± 18 477.3 
741 101.6 53.9 55.0 ± 0.7 1646 ± 51  451 ± 25 1250.0 
*Calculations based on an estimate molecular weight of 30 kDa HA.  Lots were 29 kDa and 31 
kDa.  DLS and SEC data were performed for the 29 kDa HA lot. **Standard Deviations were 
based on running the same samples for three different runs. 
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3.3.2. HA-Fluorescent Dye Conjugation Efficiency 
 In general, the conjugation efficiency of the IR hydrazine dye decreased with increasing 
molecular weight (Table 3.2).  The smaller HA molecules (7 and 30 kDa) had similar conjugation 
efficiencies that were nearly double the conjugation efficiencies observed for larger HAs (215 
and 741 kDa).  The 67 kDa HA had a conjugation efficiency intermediate to the smaller and 
larger HA. 
 
Table 3.2: Conjugation efficiency of HA in the different reactions to IR dye, tyrosine, and HA-




















7 72.3 1.6 32.7 12.1 
30* 69.7 2.4 83.3 11.1 
67 50.5 2.3 83.6 11.5 
215 38.3 2.3 88.9 2.8 
741 36.6 NA 41.1 1.6 
* Lots were 29 kDa and 31 kDa.  Conjugation efficiency of IR dye was performed on the 31 kDa 
HA lot, while conjugation efficiency of tyrosine, conjugation efficiency of 125I, and concentration 
of HA in intratracheal instillation solution data were performed for the 29 kDa HA lot.  NA 
represents not available. 
 
3.3.3. Lung Distribution and Clearance of HA-IR Dye Conjugates  
 HA-IR dye conjugates were used in a pilot study to help determine HA residence in the 
lung and to guide the selection of optimal time points and duration for the radiolabeled HA 
studies.  Each mouse received 1 mg/mL of HA-IR instilled at the top of the trachea.  Tissue 
samples were imaged at 1, 8, and 24 hours.  Each polymer was detected in all five lobes of the 
lungs for all three time points (Figure 3.2).  The distribution of HA with different molecular 
















Figure 3.2: Fluorescent images of lungs injected with HA-IR showing distribution though out all 
lung lobes with all five different molecular weights.  A: lungs injected with 5 µL of 7 kDa HA 
solution, B: 7 kDa HA 8 hour, C: 30 kDa HA 8 hour, D: 67 kDa HA 8 hour, E: 215 kDa HA 8 
hour, F: 741 kDa 8 hour.  White scale bar is 1 cm.  The white numbers represent lobes of the 
lungs with 1, 2, and 3 representing mouse anatomical right lung lobes and 4 and 5 representing 
mouse anatomical left lung lobes. 
 
 The highest molecular weight HA exhibited the highest level of fluorescence at 1 hour 
(Figure 3.3).  As HA molecular weight decreased from 741 kDa to 30 kDa, fluorescence in the 
lungs correspondingly decreased.  The 215 and 741 kDa HA had significantly higher levels at 
one hour compared to the other three HA molecular weights while the two smallest HAs, 7 kDa 
and 30 kDa, were not significantly different at 1 hour.  All five molecular weights of HA had 
minimal fluorescence at 8 and 24 hours, suggesting subsequent studies should last no longer 



















































Figure 3.3: Analysis of lungs instilled with HA-IR dye. The largest molecular weight of HA had 
the longest persistence in the lungs which decreased with molecular weight.  ** Signifies 




3.3.4. Radiolabeled HA Physiochemical Properties 
HA molecular weight was determined experimentally to compare HA as received to the 
HA conjugated with tyrosine, which was used for the radiolabeled HA biodistribution studies24.  
The molecular weight of HA molecules measured using SEC were at least 2-fold (and up to 10-


























7 kDa HA 
30 kDa HA 
67 kDa HA 
215 kDa HA 
741 kDa HA 
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conjugation resulted in an apparent decrease in molecular weight compared to stock HA for all 
five molecular weights though the differences were relatively minor for 7, 30, and 67 kDa HA.  
The tyrosine conjugation efficiency was similar throughout the different molecular weights 
ranging from 1.6% for the 7 kDa HA to ~2.3% for the next three highest molecular weights 
(Table 3.2).  Subsequent 125I conjugation was straightforward.  The three middle molecular 
weights of HA (30, 67, and 215 kDa) had similar levels ranging from 83 to 89%.  The 7 kDa and 
741 kDa had lower levels of 125I conjugation, 32 and 41% respectively (Table 3.2). 
 
3.3.5. Distribution and Clearance of HA–125I Conjugates  
 Animals were instilled with different concentrations of radiolabeled HA into the lungs due 
to viscosity constraints of the test articles.  The three lowest molecular weights, 7, 30, and 67 
kDa were instilled at 11 to 12 mg/mL, while the 215 kDa HA was dosed at 2.8 mg/mL and 741 
kDa at 1.6 mg/mL (Table 3.2).  The 7, 30, and 67 kDa HAs had minimal viscosity when instilled 
into the animals, whereas viscosity increased dramatically for the 215 and 741 kDa HAs (Table 
1) 56. Viscosity increased ~3 fold between each molecular weight studied and increased 30 fold 
and 100 fold when comparing 7 kDa to 215 and 741 kDa HA, respectively.  
After instillation, high levels of HA were found in the left and right lung lobes and in the 
GI tract including the stomach and intestine (Figures 3.4-3.6 and Supplemental Figure S3.1).  
The shape of the lung exposure profiles over time was similar for all HA molecular weights with 
HA exposure peaking at an early time point and steadily declining thereafter.  The magnitude of 
peak HA exposure to the lungs (1 to 2 hours) depended on HA molecular weight (Figure 3.4).  
The 7 kDa HA had the lowest peak levels, with 30 and 741 kDa having the next highest, and 67 
and 215 kDa HA having the highest levels in the lungs (Figure 3.4).  At eight hours, 7 and 741 
kDa HA displayed the most rapid lung clearance with (approximately 75% and 50% of the initial 
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dose cleared, respectively).  In contrast, only approximately 20% of the initial dose of 30, 67, 
and 215 kDa HA that reached the lungs after intratracheal instillation had been cleared by 8 




Figure 3.4: Exposure levels of HA in the lungs averaged across both right and left lung lobes as 
a percentage of delivered dose over time for each of the five HA molecular weights.  Each point 
is an average of at least five animals with the error on each point <5% of the measurement. 
 
 The GI tract also showed significant levels of HA (Figures 3.5-3.6) after intratracheal 
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at one hour and decreased over the remaining time of the study, while 215 and 741 kDa HA 
peaked at two hours.  At the final time point of the study (8 hours), all five molecular weights of 
HA had similar levels in the stomach with approximately 5% of the initial dose remaining.  In the 
intestines, the profiles mirror the stomach but all five molecular weights peaked at one hour and 
had approximately 5% of the initial dose remaining at eight hours. 
 
Figure 3.5: Exposure levels of HA in the stomach as a percentage of delivered dose over time 
for each of the five HA molecular weights.  Each point is an average of at least five animals with 












































Figure 3.6: Exposure levels of HA in the intestine as a percentage of delivered dose over time 
for each of the five HA molecular weights.  Each point is an average of at least five animals with 
the error on each point <5% of the measurement. 
 
 
 The distribution and pharmacokinetics of HA was assessed for other organs and tissues 
(Figure 3.7).  The liver and trachea had HA exposure levels of approximately 1 to 4% of the 
initial dose, while the heart, spleen, kidneys, and bladder contained only a fraction of a percent 
of the initial dose.  Interestingly, the level of HA in the trachea increased over time for all five 




























































Figure 3.7: Exposure levels of HA in the heart, spleen, liver, kidney, bladder, and trachea based 
on molecular weight with 7 and 29 kDa HA on top, 67 and 215 kDa HA in the middle, and 741 
kDa HA on the bottom as a percentage of delivered dose over time for each of the five HA 
molecular weights.  Each point is an average of at least five animals with the error on each point 
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Pharmacokinetic parameters were modeled to determine HA exposure and elimination 
from organs.  HA half-life in the lungs and heart generally increased as HA molecular weight 
increased (Table 3.3).  As HA molecular weight increased from 7 kDa to 215 kDa, half-life 
increased in the lungs from 2 hours to nearly 15 hours, but 741 kDa HA had a short half-life (4.9 
– 7.5 hours) in the lungs.  Half-lives for the other organs appeared relatively consistent across 
the various HA molecular weights with the exception of the heart (Table 3.3).  The heart half-life 
increased from 3.7 hours to 13.5 hours as HA molecular weight increased from 7 kDa HA to 741 
kDa HA; however, this calculation was based on less than 1% exposure to the heart tissue.   
   










Heart Spleen Liver Stomach Intestine Kidney Bladder 
7 2.5 2.1 3.7 4.0 4.9 2.7 3.8 4.3 2.8 
30* 9.8 11.0 3.9 2.8 7.4 3.2 2.3 2.9 1.7 
67 9.5 10.8 5.5 9.0 4.5 3.5 5.4 6.7 5.7 
215 29.8 14.7 7.4 3.4 3.8 4.6 1.8 2.6 2.4 
741 4.9 7.5 13.5 17.8 5.6 3.2 3.0 7.8 ND 
*HA molecular weight of 30 kDa was comprised of lots of 29 and 31 kDa.  ND – not determined. 
 
Area under the curve (AUC)31 trended similarly to the half-lives calculated for the 
different HA molecular weights (Table 3.4).  AUCs increased as HA molecular weight increased 
from 7 to 215 kDa HA, but sharply declined for the 741 kDa HA.  The low levels of HA exposure 
to the heart increased as HA molecular weight increased.  Other organs exhibited relatively 
consistent AUC values across the HA sizes studied.  Organ clearance rates were also 
calculated to describe how quickly the HA was removed from each tissue based on the extent of 
exposure of HA in each organ over time (Supplemental Table S3.1).  Clearance rates from the 
lungs decreased as molecular weight increased from 7 to 215 kDa HA, but the 741 kDa HA had 
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a higher clearance rate from the lungs, which follows earlier elimination half-life trends.  The 
heart clearance rate decreased as molecular weight increased, while the majority of the other 
organs (liver, stomach, intestine, and kidney) had clearance rates that remained relatively 
consistent as HA molecular weight increased.   
 











Heart Spleen Liver Stomach Intestine Kidney Bladder 
7 328.2 344.4 7.42 5.15 57.3 380.1 518.5 24.7 12.12 
30* 1370.1 1363 9.11 5.31 100.2 367.8 471.9 21.6 8.38 
67 1913.3 1797.0 12.09 11.59 80.8 471.7 788.0 40.0 13.31 
215 4471.2 2305.3 12.19 5.01 47.6 398.8 370.1 15.9 7.67 
741 917.3 850.2 33.95 40.33 80.6 526.0 566.0 49.2 ND 
*HA molecular weight of 30 kDa was comprised of lots of 29 and 31 kDa.  ND – not determined. 
  
3.4. Discussion 
3.4.1. Characterization of HA and Labeled HA 
HA is known to self-associate, a phenomenon which can occur within the same polymer 
chain or between different HA polymer chains.  As a result, HA has the potential to form 
secondary structures within only 6 monomer units, while tertiary structures can occur in 
polymers as small as 16 monomer units11,61,62.  These interactions can yield high viscosity 
solutions, especially for high molecular weight HA (>100 kDa).  Careful selection of high salinity 
mobile phases and dilution of samples is required to accurately analyze HA, since many 
analytical techniques for polymers are based on mobility.  For example, DLS measurements 
assume diffusion of a sphere as calculated using the Stokes-Einstein equation; however, 
changes in viscosity can result in differences in apparent size63,64.  DLS measurements reported 
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here corresponded relatively well to theoretical predictions of radii for the different HA molecular 
weights studied.  Molecular weight approximations of HA were higher than expected, but the 
trends followed as predicted from the stock HAs.   
Similarly, HA self-association has the potential to block reactive sites when attempting to 
conjugate functional groups.  The conjugation of tyrosine was quite low (~2%), while IR dye 
conjugation was much higher, suggesting poor reactivity of the tyrosine more than simple steric 
hindrance.  125I labeling, on the other hand, was quite efficient with conjugation exceeding 50%, 
which is typical for HA.  In addition, 125I labeling maintained HA molecular weight by avoiding 
reducing agents such as cyanoborohydride, which can degrade HA into smaller fragments as 
was observed with carbon-14 or tritium24,42.  Overall, conjugated HAs provided a wide range of 
molecular weights and hydrodynamic sizes for quantitatively tracking pulmonary deposition and 
subsequent distribution.   
 
3.4.2. Current Pulmonary HA Studies 
HA has been administered via several routes in a number of species to determine its 
local and systemic transport.  Most reports have focused on higher molecular weight HA (≥500 
kDa) delivered by intravenous, subcutaneous, or intrasynovial injections since these are used in 
dermal fillers and viscosupplements5,7,39.  Recently, HA has been incorporated into pulmonary 
formulations primarily as an excipient to increase dose tolerability when treating inflammation.  
Nebulized HA (300 to 500 kDa) has been administered to mice at a concentration of ~3 mg/mL 
with a total dose of 6 mg to treat lung inflammation.  HA treatment controlled inflammation by 
decreasing multiple cytokines including TNF-α and macrophage inflammatory protein-225.  
Nebulized HA formulations employing molecular weights of 300 to 500 kDa (0.1% HA) were 
given twice daily in humans to treat lung inflammation25-29.  Inclusion of HA in the nebulized 
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formulation decreased the length of hospital stay, increased tolerability of the formulation, and 
reduced lung secretions25-29.  HA has also been incorporated into drug delivery strategies to 
improve formulation characteristics.  For example, pulmonary administration utilizing spray dried 
2 MDa HA with recombinant insulin was administered to beagle dogs.  HA increased the mean 
residence time and terminal half-life of insulin in the lung41.   
Pulmonary administration includes the possibility of swallowing a portion of the dose 
directly or after mucociliary clearance.  The fate of HA after swallowing is therefore an important 
consideration when interpreting studies reported here.  Oral administration has been studied in 
both rats (100 kDa to 1 MDa HA) and dogs (1 MDa HA)20,21.  A majority of the orally 
administered HA remained in the GI tract.  There was minimal difference between molecular 
weights of HA in terms of distribution with only a slightly higher percentage observed in the 
stomach at 1 hour with 0.1 MDa HA compared to 1 MDa.  One study found that less than 10% 
and typically 1-3% of the administered dose of HA was absorbed and detected in peripheral 
tissues21.   A second study reported slightly contradictory results where only a trace amount 
(less than 0.1% of the dose/gram) of orally dosed HA entered systemic circulation20.  Both 
studies showed the vast majority of HA was eliminated in the feces (~85-95%)20,21.   
 
3.4.3. Distribution and Clearance of Labeled HA 
A pilot study was first conducted using HA-IR to determine the approximate length of 
time HA may persist in lung tissue.  After instillation, HA-IR appeared to disperse evenly 
throughout all lung lobes for all HA molecular weights.  The instilled solutions exhibited similar 
low viscosities, which may have facilitated exposure throughout the lungs due to gravity since 
mice were suspended in an upright position.  Previous studies indicated the HA-IR conjugate is 
unlikely to dissociate especially in innocuous conditions in the lungs8,34,65,66.  The highest 
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molecular weight HAs showed significantly higher lung exposure at 1 hour when compared to 
the two smallest sizes of HA.  The low lung exposures suggested that 7 and 30 kDa HA were 
rapidly cleared from the lung, since all animals received similar doses.  Molecules of this size 
are expected to be rapidly absorbed into systemic circulation32,33,67.  These pronounced 
differences compelled a more quantitative investigation of rapid HA elimination from mouse 
lungs (<8 hours) and subsequent biodistribution. 
Intratracheal instillation of HA-125I showed the vast majority of HA persisted in the lungs 
with some clear differences between different HA molecular weights.  The 7 kDa HA may have 
exhibited increased mucociliary clearance due to its high mobility and low viscosity but data 
from the trachea suggests this is unlikely.  Increased clearance for the 7 kDa HA may be 
attributed to increased systemic absorption as seen by the lowest half-life in the heart, which led 
to the highest elimination constant as well as possible urinary elimination since it is below the 
renal clearance cutoff of 25 kDa.  As seen with the increasing half-life in the heart, there is more 
systemic absorption clearance with the lower molecular weights of HA, which decreases as 
molecular weight increases.  Data showed mucociliary clearance was relatively constant for 7, 
30, 67, and 215 kDa HA suggesting macrophage uptake and passive diffusion accounted for the 
increased clearance.  As passive diffusion decreased with increasing molecular weight, 
macrophage uptake would dominate the observed clearance.  The increased persistence seen 
with 67 and 215 kDa HA could be due to saturated macrophage clearance and minimal 
clearance from the other two clearance mechanisms.  Conversely, high molecular weight and 
high viscosity of 741 kDa potentially led to retention in upper airways, thus shortening the 
distance to clear this material into the oropharyngeal cavity.  The three middle molecular 
weights of HA (30, 67, and 215 kDa) had a higher portion of HA retained in the lungs, indicating 
these doses penetrated the lungs well.   
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HA exposure to the GI tract likely resulted from a portion of the administered dose being 
swallowed or from mucociliary clearance out of the lungs followed by ingestion.  Previous 
studies have shown limited absorption of 100 kDa to 1 MDa HA and little distribution after oral 
administration with the majority of the dose being excreted in the feces or remaining in the GI 
tract20,21.  The higher level in the intestines compared to the stomach suggested gastric 
emptying over the first hour, which could be detected in future studies by more frequent 
sampling at early time points.  The profile shapes can be explained by continuous mucociliary 
clearance and swallowing followed by gastric emptying contributing to this extended GI 
accumulation period.  The trachea levels increased over time for all 5 molecular weight HAs, 
which agrees with mucociliary clearance bringing HA from the lungs continuously, independent 
of polymer size68,69.  The gastric emptying and GI motility were also expected to be independent 
of molecular weight for the entirety of the GI tract, thus providing a likely explanation for the 
similar profiles70,71.  
  The distribution and pharmacokinetics of radiolabeled HA was assessed for other 
organs and tissues (Figure 3.7).  The heart had very low levels for all molecular weights, which 
is in agreement with the short circulation half-life reported for HA.  The liver specifically 
eliminates endogenous HA, therefore rapid and continuous elimination of HA from the 
circulation by the liver was expected13,15,19.  The kidneys had lower levels than the liver but more 
than the heart, spleen, and bladder suggesting that urinary excretion may be another potential 
route for eliminating small amounts of HA absorbed systemically from the lung12-14.  HA content 
in the bladder tissue was low at all time points.  The radiolabel content of urine was not 
assessed due to difficulties in consistently collecting all urine excreted by mice without the use 
of metabolic caging.   
The 67 kDa and 215 kDa HA may provide the optimal range of size and viscosity for 
persisting in the lungs (Table 3.1).  For comparison, studies with dendrimers have shown that 
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lung persistence incrementally increased as molecular weight increased from 11 to 22 to 78 
kDa.  By increasing the size of the dendrimer, researchers observed decreased degradation 
with lower systemic exposure and greater lung retention27.  These observations correlate with 
the hydrodynamic radii observed for HAs that persisted in the lungs.  The relative hydrophobic 
character of HA may also contribute to differences in lung persistence, until HA solution 
viscosity limited penetration of the instilled dose.  The hydrophobicity of HA increases as 
molecular weight increases63.  Increasing hydrophobicity of drug delivery systems is known to 
increase clearance by macrophages, which patrol the deep lung72.  The 67 and 215 kDa HA 
may exhibit the most favorable proportion of hydrophobic character to escape significant 
macrophage clearance while retaining enough hydrophilicity for dissolution in the lung fluid and 
reduce mucociliary clearance along with mucus gel.  In contrast, the 741 kDa HA may not have 
enough hydrophilic character to facilitate dissolution in the lung fluid thus promoting accelerated 
mucociliary clearance.  The increase in size from 67 to 215 kDa could also be advantageous for 
facilitating dissolution into lung fluid, while remaining small enough to avoid macrophage 
clearance.  
 
3.4.4. Lymphatic Transport of HA  
HA naturally clears from tissue spaces through the lymphatics and has been studied as 
a vehicle to passively target drug delivery to lymph nodes.  Properties including molecular size, 
hydrophobicity57, charge58, and injection site58 affect lymphatic delivery57.  Because of its 
molecular properties, HA has the potential to traffic to the lymphatics after instillation into the 
lungs.  Here, HA exposure to lymph nodes associated with the lungs was also assessed.  
Brachial nodes draining the upper thoracic exhibited higher levels of HA compared to axillary 
nodes, but the HA levels were only ~0.02% of the initial delivered dose (Supplementary Figure 
S3.2).  There was no difference between right or left lymph node packets which correlated to the 
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similar HA levels observed in both the right and left lungs (Supplemental Figure S3.1).  It is 
noteworthy that 741 kDa HA content in the spleen was higher than other molecular weights of 
HA.  HA can bind to CD44 on immune cells, which could explain the increase.  The 741 kDa HA 
may have shown this as many endogenous HA lymphatic clearance mechanisms are for 
molecular weights larger than 100 kDa.   
Previous studies have investigated the transport of high molecular weights of HA (4.3 to 
5.5 MDA) as well as a low molecular weight HA (150 kDa) injected directly into lymph vessels of 
sheep35.  A large percentage of HA was degraded (between 48-75%) with a clearance rate of 43 
µg/hour and no HA ≥1 MDa detected in the blood.  HA of various sizes (6.4 to 697 kDa HA) has 
also been injected into the footpads of mice and the fluorescently labeled HA molecules were 
tracked54.  This study determined that HA ~30 to 50 nm in size (~75 kDa HA) had the optimal 
size to access the lymphatics54.  Similarly, 67 and 215 kDa HA were found here to persist in 
lung tissues, suggesting lymphatic transport may be augmented by persistence of the HA in 
tissues supplying the regional lymphatic network.   
 
3.5. Conclusion 
 HA is a natural biopolymer that has been used in dermal fillers and viscosupplements, 
and more recently as an anti-inflammatory therapy and delivery vehicle for therapeutics.  The 
lungs of several animal models and even humans have been treated with HA, thus compelling 
an improved understanding of HA exposure and elimination from lungs.  HAs of different 
molecular weight (7, 30, 67, 215, and 741 kDa HA) were instilled into the lungs of mice and 
tracked using a fluorescent label or a radiolabel.  HA was predominately found in the lungs and 
the GI tract.  The trachea and liver exhibited the next highest HA exposure, but these tissues 
had significantly lower amounts of HA compared to the lungs and the GI tract.  In the lungs, 7 
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kDa HA exhibited the lowest exposure levels, 30 and 741 kDa HA showed modest exposure, 
while 67 and 215 kDa exhibited the highest.  Pharmacokinetic modeling indicated 67 kDa and 
215 kDa HA offered the longest half-life in the lungs.  Also, HA was detectable in mouse lymph 
nodes draining the lungs and in spleens, suggesting radiolabeled HA may be interesting to 
study in animal models of inflammatory lung diseases.  Understanding the biodistribution and 
pharmacokinetics of different molecular weights of HA delivered to the lungs may enable 
approaches to increase lung persistence or to preferentially access selected tissue 
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Supplemental Figure S3.1: Exposure levels of HA in the lungs as a percentage of delivered 
dose over time for each of the five HA molecular weights.  A shows the right lungs, while B 
depicts the left lungs with the molecular weights displayed for each.  Each point is an average of 
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Supplemental Figure S3.2: Exposure levels of HA in the 4 extracted lymph nodes: right and 
left axillary and brachial, as a percentage of delivered dose over time for each of the five HA 
molecular weights.  Each point is an average of at least five animals with the error on each point 





















Heart Spleen Liver Stomach Intestine Kidney Bladder 
7 1.87 1.75 81.2 117.0 10.5 1.59 1.16 24.4 49.7 
30* 0.41 0.42 61.0 104.7 5.6 1.51 1.18 25.7 66.3 
67 0.30 0.32 47.5 49.5 7.1 1.22 0.73 14.3 43.1 
215 0.13 0.25 47.2 114.8 12.1 1.44 1.55 36.2 75.0 

























Using Soluble Antigen Arrays (SAgAs) 













 Inducing antigen specific immune tolerance is an emerging avenue of treatment of 
autoimmune diseases1.  The classical approach of antigen specific immunotherapy (ASIT) has 
been to desensitize the immune system through a series of subcutaneous injections.  This 
approach has generally been applied to foreign antigens (e.g. hyposensitization in the form of 
“allergy shots”).  The treatment regimen, however, requires injections over multiple years and 
disease improvement is often modest1-5.  Similar strategies have been investigated for 
desensitizating patients to autoantigens including proinsulin peptide for type-1 diabetes6, 
splicesomal peptide for Lupus7, and a pathogenic peptide for rheumatoid arthritis8.  Alternative 
delivery approaches have appeared as strategies to improve efficacy of ASIT.  Recently, new 
products including Ragwitek® and Grastek® that utilize sublingual administration to desensitize 
the immune system to foreign antigens through mucosal surfaces.  Treating the mucosal 
surfaces, such as nasal passages or lungs, may also improve performance or reduce the 
timeline required for ASIT2,5,9.     
Mucosal membranes such as nasal, buccal, and pulmonary tissues offer the first line of 
defense against exogenous antigen insult.  Mucosal barriers have multiple mechanisms to 
remove foreign pathogens and because of this, almost 80% of all immune cells constitute the 
mucosal immune system.  The mucosal immune system serves multiple purposes; protection 
from exposure to dangerous pathogens, processing of foreign antigens, and inducing 
appropriate immune responses to these foreign antigens.  The immune cells and surrounding 
tissues are part of the mucosa-associated lymphoid tissue (MALT) and are awash in foreign 
antigens compared to the rest of the immune system, which functions in a sterile 
environment2,11.  Because of the plethora of foreign antigens, MALT must also prevent damage 
to surrounding cells.  The MALT is a separate part of the immune system that functions 
independent of the systemic immune system.  There are separate distinct immune cell 
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populations with limited cycling between regions given the highly compartmentalized nature to 
reduce unwanted immune responses12-16. 
Antigen presentation is not limited to foreign antigens.  Typically, dendritic cells patrol 
the peripheral tissues including blood and lymphoid tissues taking up foreign antigens that enter 
the body.  Dendritic cells internalize and process the foreign proteins and degrade them to their 
constituent peptides, which are then processed on the surface of these cells on cell surface 
receptors including major histocompatibility complex II (MHC II).  Dendritic cells, after 
encountering certain signals, enter a process of maturation and become professional antigen 
presenting cells (pAPCs) with an increase in MHC peptide presentation16-19 .  These pAPCs are 
capable of inducing differentiation of naïve T cells into mature T cells that have the capability to 
counter the foreign pathogens by utilizing surface cell receptors for MHC I and II and 
intercellular adhesion molecule I (ICAM-1), for example17,20-23.  Similarly, B cells are adept at 
capturing low levels of antigen using B cell receptors; subsequently processing and presenting 
peptide epitopes on MHC II23.  Sometimes, however, the immune system can malfunction and 
attack self-antigens.  Dendritic cells and B cells can process and present self-antigens, 
activating T cells and propagating destruction of tissues.  This immune response to self-
antigens is what is seen in autoimmune diseases including rheumatoid arthritis, Celiac disease, 
Type 1 diabetes, and multiple sclerosis1,24. 
Multiple sclerosis (MS) is an autoimmune disease, where immune cells attack and 
degrade the myelin sheath surrounding neurons interrupting the transmission of electrical 
signals3,4,25,26.  Many of the current therapies approved for MS focus on treating inflammation or 
neurological symptoms including loss of balance, degrees of paralysis, and a loss of 
coordination.  Fewer efforts have aimed to correct the underlying immune response leading to 
the symptoms.  If this autoimmunity is uncorrected, patients can experience progressive cycles 
of remission and relapse, where periodic symptoms are followed by remission, but the patient 
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does not fully recover to the previous baseline.  There are different forms of this disease: 
secondary progressive, primary progressive, progressive relapsing, and relapsing remitting, 
which affects a majority of patients, approximately 80%4,25,26.  Experimental autoimmune 
encephalomyelitis (EAE) is the murine model of relapsing and remitting MS and is induced by 
an epitope from proteolipid protein (PLP), a component of the myelin sheath.  In this model, 
mice exhibit a peak of disease followed by remission over the course of approximately 25 
days3,4,24. 
An approved therapy for MS, Copaxone® is a random polymer of glatiramer acetate 
comprised of glutamic acid, lysine, alanine, and tyrosine, which are found in myelin basic 
protein, a component of the myelin sheath3,27.  Copaxone® acts similarly to some aspects of 
conventional ASIT.  Copaxone® potentially generates tolerance by inducing regulatory T cells, 
but the mechanism is still under investigation.  One issue with Copaxone® is that it is prescribed 
to treat the symptoms of MS and to prevent a relapse, and reversal of the underlying cause of 
immune dysregulation has not been observed27.   
An alternative approach to Copaxone® is the creation of multivalent soluble antigen 
arrays (SAgAs) comprised of a hyaluronic acid (HA) polymer backbone with grafted epitope 
from proteolipid protein amino acids 139-151 (PLP) from the myelin sheath, and a grafted 
peptide inhibitor of cell surface receptor intracellular cell-adhesion molecule-1 (ICAM-1)3.  
Previous work has shown that pulmonary delivery of SAgAs had increased efficacy compared to 
subcutaneous and intravenous delivery4.  By co-delivering these peptides, SAgAs desensitize 
the immune response to PLP, but further study was necessary to determine which individual 
components are key in eliciting the toleragenic immune response that ameliorate EAE in mice 




Table 4.1: Description of each component investigated in EAE mouse studies. 
Components Description Cartoon Representation 
Phosphate Buffered 
Saline 
Negative control NA 
HA Delivery vehicle 
 
LABL 








Multivalent therapeutic of HA, 
PLP, and LABL 
 




4.2. Materials and Methods 
4.2.1. Materials 
Hyaluronic acid (HA) molecular weight 16 kDa was purchased from Lifecore Biomedical 
(Chaska, Minnesota).  Aminooxy-LABL (AoLABL) and Aminooxy-PLP (AoPLP) peptides were 
obtained from PolyPeptide Inc (San Diego, CA).  Incomplete Freund’s Adjuvant Oil and 
Mycobacterium tuberculosis were obtained from BD Difco Adjuvants (Franklin Lakes, New 
Jersey) and pertussis toxin was purchased from List Biological Laboratories, Inc. (Campbell, 
California).  The mouse laryngoscope was purchased from Penn-Century (Wyndmoor, 
Pennsylvania).  All water used was deionized (DI) water from a Labconco Pro PS system.  All 
other chemicals and materials including 3500 Da molecular weight cutoff dialysis tubing, bent 
fine dissecting forceps, glacial acetic acid, sodium acetate, sodium phosphate monobasic 
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monohydrate, sodium phosphate dibasic, and phosphate buffered saline were purchased from 
Fisher Scientific (Pittsburgh, Pennsylvania). 
 
4.2.2. Soluble Antigen Array (SAgA) Synthesis  
The purified peptides were conjugated onto HA.  In 20 mM acetate buffer pH 5.5, a 
concentration of 2 mg/mL of 16.9 kDa HA was made.  AoLABL and AoPLP peptides were 
added in equal molar proportions, then were added to the 2 mg/mL HA solution using a ratio of 
2 HA monomers to 1 Ao peptide.  The reaction was allowed to proceed for 24 hours at room 
temperature.  After 24 hours, the reaction mixture was added to 3500 Da molecular weight 
cutoff dialysis tubing using DI water as the dialysate for 24 hours with the dialysate being 
changed every 6 hours.  Samples were then frozen ad lyophilized for 72 hours at a temperature 
of -72 °C at a vacuum of <300 millitorr (VirTis Feezemobile-12XL, The Virtis Company, NY). 
SAgAs had their peptide loading analyzed using reverse phase high performance liquid 
chromatography (RP-HPLC) and size exclusion chromatography (SEC).  SAgAs were dissolved 
in 0.1 M HCl pH 1.0 for 4 hours to hydrolyze peptides from the HA backbone.  With the HPLC, a 
calibration curve of free peptide was employed to determine the amount of peptide that was 
conjugated to the HA for SAgAs, which was compared to the relative size ascertained from 
SEC.  The HPLC method employed was performed using a Waters 2487 dual absorbance 
detector and a Waters 2796 bioseparation module.  The HPLC method employed was a 
gradient system with mobile phase A comprised of 94.9% Di water, 5% acetonitrile, and 0.1% 
trifluoroacetic acid and mobile phase B comprised of 99.9% acetonitrile and 0.1% trifluoroacetic 
acid.  The solvent system was 100% A from 0 to 15 minutes, 85% A/15% B at 15 minutes, 83% 
A/17% B at 20 minutes, 80% A/20% B at 33 minutes, 75% A/25% B at 42 minutes, 30% A/70% 
B at 43 minutes, and 100% A at 46 minutes until 60 minutes with a total flow rate of 1 mL/min.  
129 
 
A C18 Higgins Analytical Proto200, 5 µm, 200 Å, 250 × 4.6 mm2 column was used with an 
injection volume of 30 µL using samples with a concentration of 1 mg/mL with wavelength 
detection at 220 nm.     
SEC was employed to determine the increase in size of SAgA from HA due to the 
conjugation of peptides.  The system used included a Waters e2695 separation module, Waters 
2414 refractive index detector, and Waters 2489 UV/Vis detector with two columns in series: a 
PL Aquagel-OH 60 Analytical SEC (300 x 7.5 mm) then a PL Aquagel-OH 40 Analytical SEC 
(300 x 7.5 mm).  The mobile phase employed for SEC was of 0.1M ammonium acetate with 
0.136M sodium chloride at pH 5 using an isocratic system.  Samples injected were 80 µL at a 
concentration of 5 mg/mL with a total flow rate of 0.5 mL/min flow.  Samples were dissolved in 




SJL/J mice (female, 4 weeks old) were supplied by Harlan Laboratories (Indianapolis, 
IN) for the study.  Mice were approximately 13-16 g and were weighed throughout the course of 
the experiment.  The mice were housed in a pathogen-free facility at the University of Kansas 
approved by the Association for Assessment and Accreditation of Laboratory Animal Care 
(AAALAC).  Mice were maintained on a 12 hour light/dark cycle and were fed standard rodent 
pellets with no dietary restrictions or withheld food with water always available.  All animal 





4.2.4. Induction of Experimental Autoimmune Encephalomyelitis (EAE) and Time 
Course of Study 
 Each SJL/J mouse had EAE induced on study day 0 with 4 injections of an emulsion of 
Incomplete Freund’s Adjuvant Oil, Mycobacterium tuberculosis, and 200 nM of PLP.  Each of 
the 4 injections was 50 µL given subcutaneously: 2 above the shoulder blades and 2 above the 
rear hip haunches.  Each SJL/J mouse had 100 µL of 200 ng pertussis toxin injected 
intraperitoneal on day 0 as well as day 2.  There were 6 mice in each of the groups split into 2 
cages of 3 mice. 
 Over the course of the 25 day study, each mouse was weighed and given a clinical 
score from study day 7 to 25.  The clinical scoring ranged from 0 to 5 with half integer values 
and a higher score correlated to an increase in disease progression.  The advancement of the 
scoring was as follows: 0 corresponded to no symptoms of disease; 1 with a limp tail and 
waddling gait; 2 with partial leg paralysis and increased alteration of gait; 3 with paraplegia or 
complete hind leg paralysis; 4 with partial front leg paralysis; and 5 with complete front leg 
paralysis or moribund.  Half integer values corresponded with disease progression between 
scoring levels3,4. 
 
4.2.5. Treatment Schedule and Pulmonary Instillation of Compounds  
 Treatment was administered on study days 4, 7, and 10.  Before treatment, each of the 
study compounds was dissolved in sterile phosphate buffered saline (PBS).  The study groups 
were PBS, 16 kDa HA, LABL, PLP, SAgA, and bifunctional peptide inhibitor (BPI).  Each animal 
had 50 µL of each compound corresponding to 200 nM with the exception of BPI, which was 
150 nM administered via pulmonary instillation as described in detailed below3,4.  All the 
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statistical analyses were performed on Prism GraphPad 5 software, using ANOVA analysis. 
Tukey post-hoc analysis was applied to the data. 
For lung administration via pulmonary instillation, each animal was anesthetized with 2% 
isoflurane in an induction chamber for approximately 4 minutes.  After the mouse was fully 
anesthetized, the mouse was positioned in dorsal recumbency using a dosing board at 
approximately 60° to a supine position suspended by incisor teeth using a thin wire.  A nose 
cone was used to maintain anesthesia.  The mouth was opened and the tongue was gently 
pulled out and to the side of the mouth.  A laryngoscope was then positioned to depress the 
tongue and visualize the vocal cords at the top of the trachea.  A 50 µL solution of HA was then 
pipetted at the top of the trachea.  The tongue was withheld for at least 3 breaths, after which 
time the mouse was maintained under anesthesia for an additional 3 minutes on the dosing 
board.  The mouse was then removed from the dosing board and allowed to recover from the 
anesthesia by being held vertically until movement was regained28. 
 
4.3. Results  
4.3.1. Characterization of SAgAs 
 Reverse phase chromatography was utilized to determine the amount of peptide 
conjugated to HA.  Based on the RP-HPLC results, there was approximately 5 to 6 PLP 
peptides and 7 to 8 LABL peptides conjugated per polymer chain.  By determining the number 
of peptides conjugated, the approximate average molecular weight calculated using both SEC 





Table 4.2: Characterization of SAgAs and peptide loading. 
Average 









Weight of SAgA 
AoLABL:AoPLP AoPLP:AoLABL 
5.8 7.5 33000 1.3 0.78 
 
4.3.2. Co-Delivery of Peptides via SAgAs Offers Improved Therapeutic Efficacy 
 The co-delivery of peptides using SAgAs was necessary for ameliorating EAE 
symptoms.  The mice were treated on study days 4, 7, and 10, as was previously established in 
earlier publications.  The PBS group had high clinical scores that were similar to the group 
treated with LABL (Figure 4.1).  Both groups had scores that increased as of day 10 with the 
PBS group having the highest scores between days 12-15 and peaking on 14, while LABL 
peaked slightly earlier at day 12.  Both PBS and LABL remained high throughout the course of 
the study ending with scores of approximately 1.0.  The HA group had a slightly delayed onset 
of disease as disease was observed at day 11 with a peak on day 14 and a decrease to near 
baseline values by day 18.  The PLP group had similar scoring to the BPI group with scores 
remaining around 0.5 after disease onset.  The SAgA group had lower scores throughout the 
length of the study with scoring ranging between approximately 0 and 0.25, but were not 



























Figure 4.1: Clinical scores throughout the study from each of the 6 groups: PBS 
control, HA, LABL, PLP, SAgA, and BPI.  Panel A depicts all 6 groups; Panel B shows 
PBS, HA, and SAgA; Panel C represents PBS, PLP, and SAgA; and Panel D depicts 
PBS, LABL, and SAgA.  Each point is the average of 6 animals with the standard 
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 The area under the curve (AUC) from clinical scores in Figure 4.1 provides a holistic 
view of the disease state of EAE mice (Figure 4.2).  The PBS group had the highest AUC of 
approximately 20 with LABL being similar.  HA showed a decreased AUC compared to LABL 
and PBS but was higher compared to both PLP and BPI.  Again, BPI and PLP were quite 
similar, approximately 4-5, in terms of AUC.  SAgA had the lowest AUC value throughout the 






Table 4.3: Significance of clinical scores throughout the study from each of the 6 
groups.  Significance is compared between two groups with listed days showing 


















PI PBS PI 16 kDa HA PI PLP PI LABL PI SAgA PI BPI 
PI PBS X p<0.01 p<0.01 NS p<0.001 p<0.01 
PI 16 kD 
HA 
p<0.01 X p<0.05 NS p<0.0001 NS 
PI PLP p<0.01 p<0.05 X NS p<0.05 NS 
PI LABL NS NS NS X p<0.05 NS 
PI SAgA p<0.001 p<0.0001 p<0.05 p<0.05 X NS 
PI BPI p<0.01 NS NS NS NS X 
 
 
Figure 4.2: Area under the curve (AUC) of clinical scores throughout the study from 
each of the 6 groups.  Each group is the averaged aggregate total of the scores from 
the individual animals over the entirety of the 25 day long study. 
Table 4.4: Significance of AUC values based on accumulative clinical scores 
throughout the study from each of the 6 groups.  Significance is compared between two 




 The incidence of disease was also determined (Figure 4.3).  Mice are considered 
‘diseased’ when progressing to a score of 1.0 or higher, corresponding to symptoms affecting 
the rear legs as well as the tail.  The PBS, HA, and LABL groups had a rapid progression to 
disease with HA and PBS showing all the animals were sick by day 14 and all LABL-treated 
animals by day 17.  The PLP group had only 1 animal remain disease free throughout the 
course of the study.  The BPI group had 4 of 6 animals remain disease free, while the SAgA 
group had 5 of the 6 animals remain disease free.   
 
 
Figure 4.3: Incidence of disease, (when clinical score exceeds 1.0) throughout the 
study from each of the 6 groups (PBS control, HA, LABL, PLP, SAgA, and BPI).  







PI PBS PI 16 kDa HA PI PLP PI LABL PI SAgA PI BPI 
PI PBS X NS p<0.05 NS p<0.001 p<0.01 
PI 16 kD 
HA 
NS X NS NS p<0.001 p<0.01 
PI PLP p<0.05 NS X NS p<0.01 NS 
PI LABL NS NS NS X p<0.001 p<0.05 
PI SAgA p<0.001 p<0.001 p<0.01 p<0.001 X NS 
PI BPI p<0.01 p<0.01 NS p<0.05 NS X 
 
A more quantitative measurement than clinical score is assessment of weight throughout 
the study (Figure 4.4).  The weight of the animal decreases around the onset of disease due to 
decreased mobility of the animal and general decrease of animal health.  Typically, weight 
decreases starting around day 10 and as the disease resolves, will gradually increase to a 
similar level at the end as at the beginning of the study.  By tracking change in weight, a more 
quantitative measurement can be utilized and normalized to the individual animals.  The PBS, 
LABL, and HA groups had similar decreases in weight starting on day 10 with the greatest 
decrease in weight occurring on days 14 and 15.  All three groups had similar increases with 
weight by the end of the study, recovering to levels similar to the starting weights.  The BPI and 
PLP groups, again, were quite similar with decreases in weight from day 11 to 18 but with less 
of a decrease in weight compared to PBS, HA, and LABL.  The SAgA group had almost 
continuous weight gain throughout the course of the study ending with almost a 10% weight 




Table 4.5: Significance of incidence of disease throughout the study from each of the 
6 groups.  Significance is compared between two groups with listed days showing 






















Figure 4.4: Change in weight based on normalization to the initial weight on Day 0 
throughout the study with all 6 groups (PBS control, HA, LABL, PLP, SAgA, and BPI).  
Panel A depicts all 6 groups; Panel B shows PBS, HA, and SAgA; Panel C represents 
PBS, PLP, and SAgA; and Panel D depicts PBS, LABL, and SAgA.  Each point is the 
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4.4. Discussion 
4.4.1. The Lungs and Immune Tolerance 
 Antigen-specific immunotherapies are traditionally administered via subcutaneous 
injections.  Injections of antigens can potentially transport by two mechanisms: diffusion from 
the injection site to enter systemic circulation where immune cells can take up the antigens and 
process them to generate tolerance (e.g. hyposensitization therapy) and active local uptake and 
cellular transport to lymph nodes1-5.  Mucosal delivery, including buccal (e.g. Grastek®), nasal, 
and pulmonary delivery, offers a convenient route of administration and the potential for 
improved performance.  Mucosal surfaces serve as the initial barrier to entry and are constantly 
inundated with foreign pathogens.  These surfaces have their own MALT, which includes 
specialized epithelial cells that can take up antigens and direct the antigens to antigen 
presenting cells to elicit an immune response2,5,9,10.   
 
Table 4.6: Statistical significance of percentage of weight gain throughout the study 
from each of the 6 groups.  Significance is compared between two groups with listed 
days showing significant difference.  NS represents not statistically significant. 
140 
 
4.4.2. Potential Licensing of Immune Cells in the Lungs for Immune Tolerance 
 Recent research has shown the lungs to play a more important role in the immune 
system than previously thought.  For example, the ‘Hub and Spoke’ hypothesis suggests 
immune cells in systemic circulation or in the secondary lymphoid organs such as the lymph 
nodes and spleen have to be ‘licensed’ to become active29.  Immune cells gain information so 
they can migrate to different parts of the body after they enter the lungs, or the hub.  Once these 
immune cells are imbued with this information, they then can pass through to the particular 
spoke of an autoimmune disease, such as the brain for MS, pancreas for type-1 diabetes, and 
the large intestine for irritable bowel disease.  Research has shown that activated immune cells 
specific to CNS antigens do not elicit CNS symptoms until 5 days after injection when given 
intravenously.  If these same cells are delivered into the CNS, no symptoms are seen.  More 
interestingly is that these same cells if injected into the lungs, elicit the CNS symptoms without 
the delay after approximately 1 day30,31.   
The ‘Hub and Spoke’ hypothesis is especially important for T cells to migrate to a 
particular location in the body by modifying transcription and translation of necessary molecules 
for traversing tissue known as integrins.  Tissue-specific integrins, are necessary for the 
immune cells to migrate, and these molecules have been pursued as potential therapeutics.  
The potential licensing of immune cells in the lungs of EAE mice has increasing evidence.  
Researchers are elucidating the cell populations involved, tracking the cells to determine if 
these mechanisms impact efficacy.  Modification of the immune response via MALT or systemic 
changes in autoimmunity may hinge on the ability of cells to migrate through the lungs and to 
different compartments.  Thus, the lungs provide an intriguing route of ASIT administration to 




4.4.3. Potential Immune Modulation Mechanism for SAgAs 
The pulmonary delivery of SAgA components suggested the need for co-delivery of the 
PLP antigen epitope with LABL peptide to the lungs of EAE mice.  HA has some inherent 
immune activity as it can bind to CD44+ immune cells yet no therapeutic efficacy was observed 
with the delivery of HA.  The delivery of LABL also did not change the disease state suggesting 
blocking ICAM-1, a known mediator of immune cell adhesion and co-stimulation, was not 
therapeutic.  It is possible that LABL was digested quickly by peptidases in the lungs or that it 
was quickly eliminated from the lung tissue via clearance or absorption.  Treating with PLP 
alone had increased efficacy based on AUC of the clinical scores, but most EAE mice treated 
with PLP became sick.  Animals treated with PLP had a delayed onset of disease and exhibited 
decreased scores compared to HA and LABL hinting that PLP may function as conventional 
ASIT.  If this is the case, PLP may reduce disease scores by acting as a ‘decoy’ and repeated, 
perhaps, escalating, doses may hyposensitize EAE to PLP.  Ultimately, the co-delivery of the 
peptides practically eliminated disease as seen with both BPI and SAgA suggesting that co-
delivery of both PLP and LABL was necessary for treatment.  Although only SAgA showed 
statistical benefit compared to PLP alone, this was likely due to the lower dose of BPI 
administered. 
Some of the results may be explained by looking at potential immune interactions of 
SAgAs compared to the results obtained for PLP alone and for BPI treatment.  BPI is also 
composed of the PLP peptide and the LABL peptide with a short linker connecting the two 
peptides.  When antigen presenting cells such as dendritic cells interact with T cells, they form 
an immunological synapse where the cell surface receptors coalesce into a distinct pattern32,33.  
An initial study with BPI showed the forming of an immunological synapse comprised of different 
cell surface receptors co-localizing including MHC and ICAM-1.  The study with BPI showed that 
by blocking either of the receptors led to no response and no interaction of the BPI with the cell 
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receptors, but it was not certain if this was a simultaneous or sequential process.  This work 
also suggests that a majority of the interaction is cell surface mediated providing further 
evidence for the use of LABL, an ICAM-1 cell surface receptor ligand34.   
Besides the cellular aspect, there is the need to consider transport.  Previous work on 
SAgAs has reported a range of physical sizes based on the HA polymer polydispersity and the 
amount of peptide conjugated.  The physical size has typically ranged from 3-10 nm4.  This size 
range can potentially allow different physiological compartments to be accessed as the largest 
of these, 10 nm, can potentially be excluded from absorption into systemic circulation and 
passively drain to the lymphatics35-37.  Finally, active binding to immune cells and transport to 
secondary lymphoid organs may be the most likely mechanism of SAgA efficacy.  Future 




 Restoring immune tolerance in autoimmune diseases has been an important avenue of 
research especially with their increasing prevalence.  ASIT has been used for decades to 
desensitize patients to allergens, but similar approaches applied to autoimmune disease have 
yet to achieve robust clinical success.  Traditional allergy desensitization strategies have 
employed injections, while new approaches have achieved immune tolerance by applying ASIT 
to mucosal membranes (e.g. Grastek® and Ragwitek®), suggesting the lung may also provide a 
viable target tissue.  SAgA molecules exhibiting grafted antigen and a grafted inhibitor of 
immune cell adhesion or signally may amplify the effect of traditional ASIT.  SAgAs with grafted 
PLP and LABL delivered into the lungs of EAE mice showed increased efficacy based on 
clinical scoring, weight gain, and incidence of disease compared to the individual components.  
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SAgAs may, therefore, provide a more potent ASIT to restore immune tolerance to self-antigens 
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5.1. Conclusions and Future Directions  
5.1.1. Potential Opportunities for Pulmonary Drug Delivery Challenges 
 Classical pulmonary therapies have focused on treating local lung diseases such as 
asthma, COPD, and tuberculosis.  Many of these therapies have utilized small molecule 
formulations and continued development has been employed to increase duration and efficacy 
of these treatments.  There are still many challenges remaining with the treatments available as 
there is a growing prevalence of respiratory diseases complicated by poor patient compliance 
for some of the diseases.  To improve compliance, longer duration or persistence can be utilized 
but the strategy to achieve this can take many forms.  To increase duration, there is the 
potential to achieve a faster onset by increased dissolution or by modified release by employing 
particle engineering or incorporating polymers.   
Many of these approaches have focused on local treatment and delivery for lung 
diseases.  The lung may provide a potential systemic delivery platform.  The lung interplays with 
several different organ systems as there is only a minimal physiological barrier between the 
alveoli and the cardiovascular system.  The lungs have recently been identified as an important 
part of the immune system allowing for the potential to influence the immune response and 
possibly accessing the lymphatics.  By delivering different therapeutics to the lungs, different 
systemic responses can be achieved along with the potential to modulate the immune system 
for autoimmune diseases.  
 
5.1.2. Outline of Dissertation Chapters and Conclusions 
Chapter 2 focused on particle engineering microparticle NanoClusters, which were 
comprised of nanoparticle agglomerates, and assessed their characteristics and dissolution 
profile.  Particle engineering has been a drug delivery strategy employed in pulmonary drug 
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delivery to create increased deposition into the lungs or controlled release therapeutic systems.  
Depending on the properties of the particles, they have the potential to be cleared by lung 
clearance mechanisms before they can dissolve to elicit their therapeutic effect as many of the 
drugs are poorly water soluble.  By wet milling these poorly water soluble compounds, 
nanoparticle agglomerate microparticles were formed called NanoClusters.  MFI, DLS, and SEM 
confirmed that the particles were microparticles mainly between 1-5µm in size that were 
comprised of nanoparticles of several hundred nanometers.  Characterization by DSC and 
PXRD showed that the NanoClusters remained crystalline even with extended milling time.  
BET surface area analysis showed an increase in surface area of approximately 8 times for 
budesonide and 10-15 times for danazol compared to the micronized stock.  The increase of 
surface area modeled by the increased void spaces between nanoparticles in the microparticles 
was hypothesized as the reason for the enhanced dissolution.  NanoClusters had dissolution 
similar to a nanoparticle suspension even though they were much larger in size.  NanoClusters 
provide a particle engineering strategy that combines the ability to achieve a high delivery 
fraction into the deep lung with the capability to readily dissolve before being removed by lung 
clearance mechanisms.  NanoClusters achieve these improved properties without the aid of 
excipients that could disrupt the lung surface. 
Chapter 3 focused on the biodistribution and pharmacokinetics of a polymer drug carrier 
HA.  HA, given its potential for different chemistries and availability in a multitude of molecular 
weights, has been utilized in many different products.  Different administration routes have been 
investigated including intravenous and subcutaneous and the distribution has been determined.  
HA has been recently employed in nebulized formulations, but the distribution and other 
properties has yet to be determined.  HA of different molecular weights (7, 30, 67, 215, and 741 
kDa) was labeled with either a fluorescent or radiolabel then administered to mice via pulmonary 
instillation.  Size characterization was performed with SEC and DLS and was shown to have a 
well distributed size range even with label conjugation.  The fluorescent study as a pilot showed 
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no difference in distribution throughout the lung lobes based on molecular weight but that the 
two highest molecular weights had higher levels at 1 hour, which decreased at 8 hours.  The 
radiolabel portion showed the lungs and GI tract had the highest levels of HA, much higher than 
the heart, spleen, trachea, lymph nodes, liver, kidneys, and bladder.  In the lungs, the 7 kDa HA 
had the lowest levels followed by 30 and 741 kDa, while 67 and 215 kDa had the highest levels 
throughout the 8 hours studied.  Pharmacokinetic analysis agreed with the scintillation data with 
7 and 741 kDa having lower values compared to 67 and 215 kDa HA.  This work provides a 
basis for improved persistence of pulmonary therapeutics by employing molecular weight.  
Polymers are being used more frequently as advanced drug delivery strategies, and by 
investigating how their physical size and molecular weight determine their distribution after 
pulmonary administration, polymer based lung therapeutics can have increased efficacy and 
reduced side effects. 
Chapter 4 built on chapter 3 as HA had peptides conjugated and delivered into the lungs 
to stimulate immune modulation in EAE in mice.  EAE, an animal model of MS, is caused when 
immune cells attack the myelin sheath.  Previous treatments to induce tolerance have focused 
on inducing tolerance to foreign antigens, but here the approach is utilized for eliciting tolerance 
to self-antigens.  Increased efficacy has been shown by delivering SAgAs to the lungs instead of 
using other administration routes possibly due to the newly determined role of the lungs in the 
immune system.  The different components of SAgA were delivered into the lungs as were 
controls of PBS and BPI.  SAgA showed increased efficacy in terms of clinical scoring, 
incidence of disease, and weight gain compared to the individual components and negative 
PBS control and similar to the positive BPI control.  Although one component, PLP showed 
more efficacy than the other individual components, it was still less effective than the combined 
SAgA.  This work further implicates the lung as an immunologically active organ.  The lung 
serves as a delivery target that can block the progression of autoimmune diseases by co-
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delivery of antigens that can be potentially harnessed for other autoimmune diseases to 
increase the efficacy of potential therapeutics. 
 
5.1.3. Future Directions of Dissertation Chapters 
 Particle engineering can provide a multitude of opportunities in the future.  Besides the 
current methods for increasing deposition and the fraction of dose delivered into the lungs, 
dissolution can be one way to modulate release.  This work has focused on increasing 
dissolution, but by employing other drugs or the addition of excipients, the dissolution could be 
extended for a potential long acting/sustained release system.  By increasing the duration by 
modifying dissolution not just in the lungs, but in other body compartments such as joints for 
rheumatoid arthritis, it is possible to improve patient outcomes.  The next step would be testing 
NanoClusters, both by inhalation (and possible injection) in animals to determine the 
pharmacokinetic profile.  Gaining this information across multiple drug classes besides 
corticosteroids, could validate NanoClusters as a modified release platform. 
 Inhaled formulations of HA, or other polymers, allow for increased possibilities in 
inhalation therapies.  Polymers, like particle engineering, can be utilized for modified release 
profiles and have been to an extent in treating tuberculosis locally in the lung.  The addition of 
polymers as a vehicle could allow for access to different body compartments allowing the lungs 
to be employed as a potential platform for systemic delivery.  The next step in this work would 
be to radiolabel and track HA in real time.  By using a PET scanner to follow the labeled HA in 
mice, particularly in the same animal over time, would provide a clearer profile of the polymer 
distribution with enhanced time points and power.  Also, labeling other polymers including 
polysaccharides dextran and chondroitin, as well as classical polymers like polyacrylamide over 
a smaller size range from 50 to 250 kDa would better determine polymer clearance from the 
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lung based on molecular weight.  The addition of this information could potentially provide the 
basis for a statistical model for polymer lung pharmacokinetics.  
 The final work with SAgAs was already a partial future direction of chapter 3 by making 
the polymer a therapeutic.  The next step of this work encompasses multiple avenues.  The 
immune system is composed of many cells types (B cells, T cells, dendritic cells, etc.) and 
determining which cells are involved would better elucidate the mechanism of SAgA action.  A 
better understanding of action could provide an improve set of criteria for synthesizing the 
SAgA.  Modifying the size of the SAgAs by varying the molecular weight of the HA backbone 
could provide increased efficacy at a lower dose via pulmonary instillation with further testing.  
Finally, by labeling the SAgAs, it could be tracked throughout the animals to determine which 
body compartments and tissues are important for the efficacy, which can lead to further 
optimization of SAgAs.  Real time PET tracking with radiolabeled SAgAs would allow dose 
schedule optimization, which is important in advancing this therapy into humans and could 
provide a further understanding for the mechanism of action. 
 Pulmonary drug delivery has been a fairly limited space in the pharmaceutical world.  
Most of the current products focus on treating lung diseases with local administration from lung 
delivery platforms (DPI, pMDI, and nebulizers).  There are only a few drug classes primarily 
corticosteroids, bronchodilators like β2 agonists, and antibiotics that are delivered and only a 
small fraction of the dose is deposited into the lung to elicit the therapeutic effect.  Continued 
research in pulmonary drug delivery in both academic and industrial settings are necessary to 
expand this underutilized delivery route that has increased promise both locally as well as 
systemically to improve patient outcomes.  My contributions as stated in this dissertation serve 
to enhance the sphere of delivery to the lungs by employing multiple techniques (particles and 
polymers).  Further broadening these techniques serve as mechanisms to increase onset time 
by the enhanced dissolution of NanoClusters, enhance deposition into the lungs, increase 
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persistence and decrease accessing unwanted organs by employing the proper molecular 
weight of the polymer therapeutic, and employing immune modulation via SAgAs, which all 
further broaden how the lung can be employed as an delivery target by enhanced therapeutics. 
 
